The Global NASH Council ™

The Global NASH Council ™ has been formed to bring together international experts to discuss, collaborate and contribute to the field of NASH. Given the global nature of NAFLD and NASH, it is important to include perspectives from different regions of the world, assess the clinical and economic impact of NASH based on the realities of each country and region. The Global NASH Council ™ meets in person twice per year as well as communicate through several Web-meetings. The in-person meetings are designed to discuss new topics in the field of NASH and design joint projects that will contribute to the understanding of this important liver disease. The Council members also form selected collaborative teams to address specific issues such as region-specific economic impact of NAFLD. Most members of the NASH Global Council ™ are also active participating sites for the the Global NASH Registry ™ and Global Liver Registry ™.

The Members of the Council are growing but include the following:

Medical Education:
University of Rochester School of Medicine (MD).
Current Academic or Administrative Positions:
Professor and Chairman of the Department of Medicine, Inova Fairfax Medical Campus
President, Inova Medicine, Inova Health System
Area of Research interests:
Pioneering research in non-alcoholic fatty liver disease, patient reported outcomes, health-related quality of life, economic analysis and outcomes research in liver disease.
Publications and Presentations:
Authored over 700 articles, 3 books, 6 journal supplements, over 25 book chapters, over 1000 abstracts at the international scientific meetings and over 470 faculty lectures. His current H-index is 103 (July 2022).
Comments:
Zobair M. Younossi, MD, MPH is the Professor and Chairman of the Department, Inova Fairfax Hospital, Falls Church Virginia. He is also the President of Inova Medicine, Inova health System, Falls Church, VA. Dr. Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York (Alpha Omega Alpha, 1989), and completed his residency in internal medicine as well as a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. During his residency and fellowship, he earned his master of public health degree from San Diego State University (SDSU) School of Public Health in San Diego, California, being awarded the Hanlon Award and Outstanding Student Award for SDSU. He then served as the Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio (1995-2000). Dr. Younossi established Center for Liver Diseases at Inova Fairfax Hospital in 2000 which is renowned in research related to non-alcoholic fatty liver disease (NAFLD) and Outcomes Research in liver disease. He has served as the Vice President of Research for Inova Health System (2007-2018), Chairman of Clinical Research for Inova Health System (2019-2022), member of the Board of American College of Gastroenterology Institute, member of the Board of Inova Health System Foundation and is the current Chairman of Board of Trustee for The Chronic Liver Disease Foundation (CLDF). He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

Dr. Younossi's academic experience also includes being the co-editor of Liver International, Associate Editor of J of Hepatology and serving on the editorial board of a number of important medical journals. Dr. Younossi has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to study NAFLD and PROs in liver disease through global collaborations. In addition to research, Dr. Younossi has been actively involved in teaching students, residents and fellows. He has also served as the Chair, the Director or the Faculty for a number national and international scientific and CME related programs.

Medical Education:
Fellowship: Stanford University Gastroenterology Fellowship (1999) CA
Internship: Dow Medical College (1991) Pakistan
Medical Education: Dow Medical College (1990) Pakistan.
Current Academic or Administrative Positions:
Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center.
Member, Stanford Diabetes Research Center
Area of Research interests:
Nonalcoholic fatty liver disease (NAFLD) and viral hepatitis.
Publications and Presentations:
Over 150 publications and presentations.
Comments:
Dr. Ahmed’s research interests include nonalcoholic fatty liver disease (NAFLD) and viral hepatitis. He has focused my research to database analysis/outcomes and translational research in these areas. While database analysis has been critical in outlining trends in NAFLD and viral hepatitis epidemiology, translational research has provided insight into disease mechanism and future therapies. He collaborates with several basic science colleagues and act as clinical mentor for young investigators involved in translational research. He is also interested and act as adjunct faculty in biodesign and health policy. He has participated in several clinical trials as a co-investigator.

Medical Education:
Gr. T. Popa University of Medicine and Pharmacy (2005) MD
Saint Louis University School of Medicine (2010) Residency
Saint Louis University School of Medicine (2011) Chief Resident
Gastroenterology Fellowship Program, Programs in Rochester, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine (2014)
Transplant Hepatology Fellowship, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine (2015)
BASIC SCIENCE MASTERS, Clinical and Translational Science, Programs, Mayo Graduate School, Mayo Clinic College of Medicine (2023)
Current Academic or Administrative Positions:
Gastroenterologist, Internist, Mayo Clinic, Rochester, Minnesota
Founder and Director of the NAFLD Clinic at Mayo Clinic, Rochester, Minnesota
Area of Research interests:
Nonalcoholic fatty liver disease, biomarker development, predictive outcome modeling, large database research, digital hepatology, artificial intelligence, epidemiology
Publications and Presentations:
Authored or co-authored more than 50 publications and presentations.
Comments:
Dr. Allen’s work aims to develop easily accessible methods for screening and predicting disease trajectory in patients with NAFLD. Early identification of this disease could improve outcomes and prevent complications such as cirrhosis, liver cancer, the need for transplantation, and death. Areas of focus include noninvasive biomarker development for NASH, individualized prediction of future development of cirrhosis and complications using MRE, population-based research using large data sets and use of artificial intelligence methods to develop predictive models of future risk of liver events and mortality. She is the founder and Director of the NAFLD Clinic at Mayo Clinic in Rochester, MN.

Medical Education:
University of Damascus (MD).
Current Academic or Administrative Positions:
Associate Professor of Medicine, University of Texas Health San Antonio (UTHSA).
Area of Research interests:
Pioneering research in non-alcoholic fatty liver disease biomarkers and drug development, Epidemiology and outcomes research in liver disease including liver transplantation.
Publications and Presentations:
Authored over 150 articles, 9 book chapters, over 300 abstracts at scientific meetings and over 100 faculty lectures. His current H-index is 38 (November 2019).
Comments:
Dr. Naim Alkhouri is the Director of the Metabolic Health Center at the Texas Liver Institute in San Antonio. He is Associate Professor of Medicine at the University of Texas (UT) Health San Antonio.
Dr. Alkhouri completed his medical degree at the University of Damascus in Syria before completing his residency at Albert Einstein Medical Center in Philadelphia and fellowship at the Digestive Disease and Surgery Institute, Cleveland Clinic in Ohio.
Among many research awards, Dr. Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. Dr. Alkhouri has over 150 publications and presents his work at both national and international medical conferences. His specialty interests include nonalcoholic fatty liver disease, viral hepatitis, autoimmune liver disease, and liver transplantation.
Dr. Alkhouri is a member of several professional organizations, including the American Association for the Study of Liver Disease (AASLD); the European Association for the Study of the Liver (EASL); and the American College of Gastroenterology (ACG).

Medical Education:
MBChB MS, King Abdul Aziz University (1999)
University of Western Ontario Schulich School of Medicine & Dentistry / Internal Medicine (2004)
University of Calgary / Gastroenterology (2007)
Mayo Clinic School of Medicine (2008)
Current Academic or Administrative Positions:
Associate Professor of Medicine, Johns Hopkins Medicine
Area of Research interests:
Drug Induced Liver Injury; Liver Cancer; Hepatitis B; Hepatitis C; Fatty Liver Disease
Publications and Presentations:
Multiple publications in international peer-reviewed journals
Comments:
Dr. Alqahtani has been the principal investigator for clinical trials related to the management of fatty liver disease and viral hepatitis including novel agents. He also is the co-investigator for numerous clinical trials in liver cancer, liver cirrhosis, and outcome of liver transplantation.

Medical Education:
MBBS from school of Medicine, King AbdulAziz University, Jeddah, the postgraduate training at King Saud University and Hepatology fellowship from University of Toronto, Canada.
Current Academic or Administrative Positions:
Associate Professor and Consultant Hepatologist, College of Medicine, King Saud University, Riyadh Saudi Arabia. Director of Liver disease research center, College of Medicine, King Saud University.
Area of Research interests:
Clinical research on Non-alcoholic fatty liver disease, viral hepatitis and non-invasive test of liver fibrosis.
Publications and Presentations:
Dr Alswat has published over 60 peer-reviewed papers and given numerous presentations on the topics of NAFLD and other liver disease.

Medical Education:
Trained in medicine at University College London where he was awarded a First Class Honours degree and won First Prize in Medicine in the final MB BS examination
Current Academic or Administrative Positions:
Chair of Experimental Hepatology and the Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK.
Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital where he leads one of the largest Non-Alcoholic Fatty Liver Disease (NAFLD) clinical services in the U.K.
Area of Research interests:
Pathophysiology, natural history, diagnosis and treatment of NAFLD.
Comments:
Prof Anstee’s translational research has made major contributions across the pathophysiology, natural history, diagnosis and treatment of NAFLD. His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. He coordinates two major international research consortia that are studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017-2023). He leads the European NAFLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for NAFLD. He is an Associate Editor of the Journal of Hepatology.

Medical Education:
M. D., University of Chile, School of Medicine (1987)
Internal Medicine Residency, Catholic University of Chile, School of Medicine (1988-1991)
Chief Resident (1990-1991), Catholic University of Chile, School of Medicine (1991)
Gastroenterology Fellowship, Department of Gastroenterology, Catholic University of Chile, School of Medicine (1991-1993)
Research Fellowship (Experimental Hepatology), Supported by the Fogarty International Center, NIH, Bethesda, MD, USA. Gastroenterology/Hepatology section, Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA (1995-1997)
Current Academic or Administrative Positions:
Professor of Medicine Head of Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile (http://medicina.uc.cl)
Area of Research interests:
Fatty Liver Disease, Bile Acids, Cholestasis, DILI
Publications and Presentations:
Professor Arrese Jimenez has published 166 articles (83 Original Papers, 36 Review Articles, 6 Invited editorials, 12 invited commentaries, 19 case reports/case series, 3 letters to the editors, 6 essays), 13 Book Chapters with 6612 citations (Google scholar, accessed Sept 24, 2018). He has given 56 international lectures.

Medical Education:
Mongolian National University of Medical Sciences (MD)
Management Academy of Mongolia (MBA)
Current Academic or Administrative Positions:
Project leader, Hepatitis free Mongolia funded by the Rotary Foundation since 2016.
Consultant and auditor of the quality management system and accreditation of healthcare organizations.
Area of Research interests:
Prevention, screening and treatment of the liver disease.
Publications and Presentations:
Authored and reviewed multiple national policy documents and presentations.
Comments:
Dr. Munkhjargal Ayurzana initiated and managed the liver disease prevention program in Mongolia funded by the Rotary Foundation. Dr. Munkhjargal conducted Country Pilot for Validation of Elimination of Viral Hepatitis as a Public Health Problem in Mongolia in 2022 with the WHO guidance. Also, Dr. Munkhjargal provided consultancy on viral hepatitis prevention and capacity building for health care workers to support Healthy Liver Program by the Government of Mongolia.

Medical Education:
Jawaharlal Institute of Post-Graduate Medical Education and Research (JIPMER), Pondicherry, India
Mayo Graduate School of Medical Education: Fellowship in Endocrinology
Current Academic or Administrative Positions:
Professor of Medicine, Division of Endocrinology, Department of Medicine.
Clinical Education Director of the Center of Diabetes Technology.
Vice Chair Institutional Review Board –Health Sciences Research, School of Medicine, University of Virginia
Area of Research interests:
Developing advanced treatments for diabetes, as well as using state-of-the-art methods she pioneered in her very productive career spanning over 20 years at Mayo Clinic and now at the University of Virginia to investigate abnormal carbohydrate metabolism in both type 1 and type 2 diabetes. Her research focusses on the pathophysiology of pre-diabetes, type 2 diabetes, and other metabolic diseases such as NAFLD/NASH and she leads an international program in education of diabetes technology. Her goal is to provide state-of-the-art technology to all patients with diabetes to improve their management and care. More information on https://med.virginia.edu/diabetes-technology/faculty/rita-basu
Publications and Presentations:
Dr. Rita Basu has more than 130 publications. Partial bibliography.
Comments:
Dr. Rita Basu, MD., is a tenured Professor in the Division of Endocrinology, department of Medicine at the University of Virginia. She was recruited from the Mayo Clinic, Rochester where she was a faculty since 1995 (career spanning 23 years) to lead a Center for Diabetes Excellence at UVA as part of their Strategic Investment Plan. She has a long history of leading clinical trials and research in integrated physiology of diabetes and remains continuously funded by the National Institute of Health in USA for three decades and is a prolific author in high impact journals. She serves on the scientific sessions planning committee for the American Diabetes Association. Professor Basu is the Clinical Education Director of a National and International program for education and training for advanced management of diabetes using technology (CGM, Pumps etc.) at the UVA. She continues to be involved in ethics and human subject’s protections. Her mission is to improve care of patients with diabetes and other metabolic disorders using state of the art technologies being developed at the UVA.

Medical Education:
Bachelor of Medicine and Surgery (MB ChB), University of Dundee, School of Medicine, Dundee, United Kingdom (2012)
Doctorate of Medicine (DM), University of Edinburgh, United Kingdom 2023 Exp
Higher Specialist training – Gastroenterology, Hepatology and G(I)M
European Specialty Examination in Gastroenterology and Hepatology (ESEGH) (2020)
Advanced Liver Transplant Training, Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, United Kingdom (2022)
Current Academic or Administrative Positions:
Clinical Lecturer (Assistant Professor) and Honorary Specialist Registrar in GI, Hepatology and G(I)M University of Dundee, School of Medicine and NHS Tayside
Area of Research interests:
Nonalcoholic fatty liver disease (NAFLD), Epidemiology and Natural history of NAFLD, Biomarker Validation, Intelligent Liver Function Testing (iLFT), Early identification strategies for liver disease, Translational Studies and Cellular Therapeutics for CLD.
Publications and Presentations:
I have authored or co-authored more than 40 publications, presentations, in addition to a number of invited national and international lectures.
Comments:
Dr Brennan’s research focuses on the utility of early detection of fibrosis and the translational space therein. Other aspects of interest relate to the use of intelligent liver function testing (iLFT) to improve the diagnosis of liver disease in primary care, in addition to the development of precision approaches for metabolic syndrome and alcohol-related liver disease (ArLD).
I also have an interest in frailty in advanced liver disease, the use of prognostic scores to aid prehabilitation and anticipatory care planning, symptom burden minimisation, and, palliative care integration in pathways of care. As a result of my doctoral studies, I continue to develop an interest in trial design in liver disease, and the utility of autologous or modified iPSC-based cell therapies in promoting advanced fibrosis resolution. Finally, I have a keen interest in health and social determinants relating to referral for transplantation, and poor outcomes relating to lower socioeconomic class.

Medical Education:
Clinical researcher graduated at the School of Medicine of the University of Bologna, Italy. Se became specialized in Internal Medicine and later PhD in Hepatology at the University of Bologna and Modena. Her post-graduate training included a PhD fellowship at the Cleveland Clinic and at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism and started a pioneering research activity on NAFLD under the guidance of Prof AJ McCullough
Current Academic or Administrative Positions:
Associate Professor of Gastroenterology, University of Torino, Italy
Area of Research interests:
Dr. Bugianesi is the national principal investigator of FP7 funded Fatty Liver: Inhibition of Progression (FLIP) consortium (2010-2013), assembling the largest cohort to date of highly phenotyped, histologically characterized patients with NAFLD for the genetics work-package and she is currently involved in other two major EU funded research consortia: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €34 million, 2017-2022), where she has the role of national lead for Italy.
Publications and Presentations:
Dr. Bugianesi has had 182 publications with Impact Factor of 1274, Scopus H-Index (1990-2019) of 56 (Scopus) and 14,584 Scopus Citations (1990-2017)
Comments:
Dr. Bugianesi is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years of experience in the field where she has made a particular impact with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease including the first demonstration of HCC as a complication of NASH-related liver disease, the development of non-invasive markers of fibrosis including the NAFLD Fibrosis score, currently recommended by the EASL-EASD-EASO Clinical practice Guidelines on NAFLD (J Hepatology, 2016) and the involvement in several trials for the treatment of NAFLD/NASH.

Medical Education:
Medical Degree at Padova University, Italy (1984).
Specialization on Gastroenterology and Endoscopy at Padova University, Italy (1988).
Visiting Researcher at Queen Elizabeth Hospital in Birmingham, UK (1988-1991).
PhD on Gastroenterology, University of Modena and Padova, Italy (1993).
Current Academic or Administrative Positions:
Full Professor of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
Head of Multivisceral Transplant Unit, Padova University Hospital, Italy.
ViceRector on Research Training, University of Padova, Italy.
Area of Research interests:
Clinical and translational studies in the setting of liver transplantation, mainly regarding antiviral therapy for HCV recurrence, HBV prophylaxis after transplantation, acute alcoholic hepatitis as early indication for liver transplantation, liver transplantation for NASH and NAFLD, adherence to medical treatments and quality of life of transplant recipients.
Publications and Presentations:
Author of 320 articles in international peer-reviewed journals, with an H-index of 52 (Scopus-January 2020) and over 1000 presentations in national and international congresses.
Comments:
She has previously served as President of ELITA, Vice President of ESOT, Chair of ILTS Education Committee, Treasurer of ILTS and ILTS President. She is now Past President of ILTS. She served EASL for 5 years, as EU Policy Councilor until 2016. She is also President of the NGO Marina Minnaja Foundation for the research and study of liver transplantation.
Currently she is Co-chair of The Lancet – EASL Commission on liver diseases in Europe from 2018, Deputy Editor of Journal of Hepatology from 2019 and Associate Editor of Transplant International and Digestive and Liver Disease.

Medical Education:
Medical Degree at the University of Barcelona
PhD in Internal Medicine at the Universitat Autònoma de Barcelona
Current Academic or Administrative Positions:
Professor of Medicine and Chief of Hepatology- Internal Medicine and at the Vall d'Hebron University Hospital in Barcelona, Spain.
Area of Research interests:
Research focus on diagnosis and therapy of vIral Hepatitis particularly Hepatitis B, C and D.
Publications and Presentations:
Published more than 450 papers the field of liver disease, with numerous papers on viral hepatitis and contributions to books.
Comments:
Dr. Buti has particípated in the commite of EASL Clinical Practice Guidelines on hepatitis B J Hepatol 2017. She has been President of the Spanish Association for the . Study of the LIver from 2017 to 2019. She is currently member of the Governing Board of the European Association for the Study of the Liver (EASL) from 2019 and EASL EU Policy Councilor

Medical Education:
University of Rome La Sapienza, Doctor in Medical Statistics, PhD in Public Health
Current Academic or Administrative Positions:
Senior Researcher at Sciences économiques et sociales de la santé and traitement de l'information médicale (SESSTIM) at the French Institute of Health and Medical Research (INSERM), Marseille, France
Area of Research interests:
Interventional research for people at risk of or living with a liver disease, liver cancer prevention, impact of social conditions and behaviours on clinical outcomes, patient reported outcomes, social inequities, stigma and harm reduction.
Publications and Presentations:
She authored approximately 400 articles including book chapters. Her current H-index is 46 (July 2022).
Comments:
For several years P. Carrieri has been coordinating a line of research on access to prevention and care for people at risk of or living with a liver disease - people who use drugs, people with unhealthy alcohol use, migrants, people with obesity. This research also integrates community-based research approaches. She is leading the public health research line of several cohorts of patients with liver disease. More recently, she has conducted research on barriers to access to care for people with alcohol use disorders, novel therapeutic interventions to reduce stigma and other alcohol-related harms and on the needs and interventions for people with NAFLD/NASH. She is member of the Scientific Committee of two French doctoral schools (ED62, ED292) and she has mentored 12 PhD students. She is also member of the Scientific Committee of Santé Publique France, the main Institute guiding public health actions to protect the health of French citizens.

Medical Education:
Medical degree from the University of Paris-VI
PhD from the University of Paris-XII
Current Academic or Administrative Positions:
Professor of Hepatology at the University of Paris-VII (Department of Hepatology, Hopital Beaujon, Clichy, France).
Visiting Professor of Medicine in University College of London (Institute of Liver and Digestive Health, Royal Free Hospital London, UK).
Area of Research interests:
Research interests focus on non-invasive methods for liver fibrosis assessment, NAFLD and viral hepatitis.
Publications and Presentations:
Published more than 180 papers in international peer reviewed journals and also serves on the editorial boards of the Journal of Hepatology, Gut and Liver International.
Comments:
Dr. Castera has been the chairman of the first international guidelines on the use of non-invasive tests (EASL-ALEH Clinical Practice Guidelines J Hepatol 2015). He has served on the Scientific Committee of the United European Gastroenterology (UEG) from 2011 to 2013 and on the Council of UEG since 2017. He has been a member of the European Association for the Study of the Liver (EASL) Governing Board from 2012 to 2013, EASL Vice Secretary from 2013 to 2015 and EASL Secretary General from 2015 to 2017.

Medical Education:
Dr. Wah-Kheong Chan received his M.B.B.S. from the University of Malaya in 2005 and his M.R.C.P. in 2008. He completed his fellowship in Gastroenterology and Hepatology at the University of Malaya Medical Centre in 2013 and his Ph.D. on non-alcoholic fatty liver disease at the University of Malaya in 2015.
Current Academic or Administrative Positions:
Professor at the University of Malaya and Senior Consultant Gastroenterologist and Hepatologist at the University of Malaya Medical Centre and the University of Malaya Specialist Centre. He is a Member of the Academy of Medicine of Malaysia and a Committee Member for the Malaysian Society of Gastroenterology and Hepatology. He is the Scientific Co-Chair for Hepatology for the Asia Pacific Digestive Week 2020. He is a member of the Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease and the Gut and Obesity in Asia (GO ASIA) Workgroup.
Area of Research interests:
Non-alcoholic fatty liver disease.
Publications and Presentations:
He has published over 50 full papers in peer-reviewed journals and presented in both local and international conferences.
Comments:
Associate Editor for the Journal of Gastroenterology and Hepatology, and is a reviewer for several international journals.

Medical Education:
Dr. Chawla did his MBBS in 1974, MD (Internal Medicine) in 1978 and DM (Gastroenterology) from AIIMS, New Delhi in 1982
Current Academic or Administrative Positions:
Former Director and Emeritus Professor, PGIMER
Former Prof. and Head, Department of Hepatology, PGIMER, Chandigarh (India)
Chairman Academics and Professor Emeritus,Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar, Member, Institute Body AIIMS, Bhubaneswar, Chairman, Academic Committee, JIPMER, Pondicherry, Member, Academic Committee, ILBS, New Delhi, Chairman, Scientific Advisory Committee, AIIMS Bibinagar, Hyderabad, Member, Governing Council, SRMC, Chennai, Member, Board of Management, JSS Academy of Higher Education and Research, Mysuru
Area of Research interests:
NAFLD, ACLF, Liver Transplantation, ALF,HCC
Publications and Presentations:
Professor Y K Chawla is author of more than 475 papers (283 International 192 National) in reputed journals including several chapters in the Gastroenterology and Hepatology text books.
Comments:
Prof Y K Chawla has been Member, American Association for the Study of Liver Diseases, Member, European Association for Study of Liver, Fellow of the American College of Gastroenterology, Member, International Association for Study of Liver, Member, Asian Pacific Association for Study of Liver. He is also The Fellow, National Academy of Medical Sciences, Life Member, Indian Association for Study of Liver (INASL), Life Member, Indian Society of Gastroenterology and Endoscopy Society of India.
Prof Chawla was the President, Indian National Association for the Study of Liver (2006-2009), Governor, American College of Gastroenterology, Indian Region (2006-2011) He is a recipient of various awards and honours from National and International societies and Government of India namely Padma Shri, the 4th highest Civilian Award. He started First DM (Three Year Fellowship) Hepatology programme in the country, Started the First Liver Intensive Care Unit in the country in a Government Hospital.

Medical Education:
Training in Internal Medicine and Gastroenterology- Hepatology from Post Graduate Institute of Medical Education & Research, Chandigarh, India.
Current Academic or Administrative Positions:
Secretary, Board of Governors, Indian Institute of Liver and Digestive Sciences, Sonarpur, West Bengal, India.
B. Professor and Head, Department of Hepatology, Institute of Post Graduate Medical Education and Research, Kolkata, India.
Area of Research interests:
Population Based Epidemiology of Liver Diseases. Pathogenesis and characterization of NAFLD in Non-Obese individuals.
Publications and Presentations:
Published more than 100 papers and five book chapters.
Comments:
Dr. Abhijit Chowdhury graduated from North Bengal Medical College and did his residency in Internal Medicine as well as Fellowship training in Gastroenterology – Hepatology at Post Graduate Institute of Medical Education and Research, Chandigarh. He joined the faculty of School of Digestive and Liver Diseases at Institute of Post Graduate Medical Education and Research, Kolkata in 1994, was the chair of the School where is serving as Professor and Head , Hepatology till date.
He is also the secretary of Liver Foundation, West Bengal – a NGO involved in research in liver diseases including Institution building and also in broader public health issues in the context of developing countries. He had been involved in establishing and development of Indian Institute of Liver and Digestive Sciences (www.iilds.in), a newly developed Institute through absolute philanthropic donation from all over the globe. Dr. Chowdhury is Director of a Health and Demographic Surveillance system (www.shds.in) for population based analytical and implementation research in Public Health.

Medical Education:
Received medical degree from Harvard Medical School in Boston, Massachusetts. Earned a PhD in physiology and biophysics at Harvard University. Completed his residency and served as a research fellow in internal medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston. Completed a clinical fellowship and a research fellowship in gastroenterology at Harvard Medical School and Brigham Women’s Hospital, and served as a senior fellow in hepatology at Brigham and Women’s Hospital.
Current Academic or Administrative Positions:
Chief of the Division of Gastroenterology and Hepatology at Weill Cornell Medical College.
Co-director of the Center for Advanced Digestive Care at Weill Cornell Medical College and New York Presbyterian Hospital.
Area of Research interests:
Lipid-mediated control of nutrient metabolism and the control energy homeostasis in the pathogenesis of obesity-related disorders.
Publications and Presentations:
Over 150 publications and more than 250 presentations. His research has been published in journals including Nature Structural Biology, Nature Medicine, Journal of Clinical Investigation, Science Signaling, Hepatology, Proceedings of the National Academy of Sciences, American Journal of Physiology, Journal of Lipid Research, Journal of Biological Chemistry, Gene, FASEB Journal, FEBS Letters, Biochemical Journal, and Biochemistry.
Comments:
Dr. Cohen is a fellow of the American College of Physicians, of the American Gastroenterological Association and of the American Association for the Study of Liver Diseases. He is also a member of the American Diabetes Association, the American Society for Clinical Investigation, the Interurban Clinical Club and the American Society for Biochemistry and Molecular Biology. Dr Cohen is the current Editor-in-chief of Hepatology. He is on the editorial boards of Trends in Endocrinology and Metabolism (Cell Press) and the Journal of Biological Chemistry. He was an associate editor for Seminars in Liver Disease. He is a reviewer for several scientific journals, including the Cell Metabolism, Nature Medicine, American Journal of Physiology, The New England Journal of Medicine, Gastroenterology, Arteriosclerosis, Thrombosis, and Vascular Biology, Journal of Clinical Investigation, Diabetes and Lipids.
He has served as a member of the NIH Hepatobiliary Pathophysiology Study Section and as Chair of the American Heart Association Lipoprotein and Lipid Metabolism Study Section, National Chapter. Finally, he is the recipient of numerous awards, including the American Liver Foundation Research Prize, an American Liver Foundation Liver Scholar Award, an International HDL Research Award, a Hirschl Career Scientist Award and an NIH MERIT Award. He was also an Established Investigator of the American Heart Association. Dr. Cohen is currently the recipient of 2 NIH R01 grants in addition the MERIT Award.

Medical Education:
Professor Colombo gained his medical degree from the University of Milan, before completing a residency in gastroenterology at IRCCS Maggiore Hospital. Subsequently he undertook an international fellowship in liver diseases at Mount Sinai Hospital in New York, USA(1974-1975), before returning to IRCCS Maggiore Hospital.
Current Academic or Administrative Positions:
Director of the Liver Center and Private General Medicine 8 at San Raffaele Hospital ,Milan,Italy and Chairman of EASL International Liver Foundation, Geneva, Switzerland.
In the past 3 years he has been Director of the Center of Translational Research in Hepatology at Humanitas Hospital, Milan, Italy.
In the previous 15 years, he has been Chairman of the Division of Gastroenterology and Hepatology and Chairman of the Department of Medicine and Liver, Kidney, Lung, Bone Marrow and Organ Transplantation at IRCCS Maggiore Hospital in Milan, Italy.
He has also been a Professor of Medicine and Gastroenterology at the University of Milan for more than 25 years.
Area of Research interests:
Professor Colombo’s research interests include the diagnosis and treatment of viral hepatitis and liver cancer.
Publications and Presentations:
Authored more than 500 original manuscripts in peer-reviewed journals, with an H-index of 104(Google Scholar) and 57,369 citations.
Comments:
A member of many professional societies including EASL, AASLD and several Italian societies, he is the recipient of numerous awards including the 2010 European Association Study Liver (EASL) Recognition Award for outstanding medical and scientific contributions, the Italian Association for the Study of the Liver (AISF) Distinguished Service Award, the Thannhauser Medal Award of the German Society of Gastroenterology and the Nelson Fausto Award of the International Liver Cancer Association(ILCA). Professor Colombo was Editor-in-Chief of the Journal of Hepatology from 2005–2009 and currently sits of the editorial boards of many hepatology journals,is Special Section Editor of Journal of Hepatology(2015-2019), Strategic Advisor of Editor of Liver International(2015-2019) and contributor of Selected Summary for Gastroenterology(2000-2021).He was Associate Editor of Journal of Hepatology in 1996-2000 and chaired the writing committees of EASL Clinical Practice Guidelines of Benign Liver Tumors in 2014 and of Occupational Liver Diseases in 2017. In September 2016 he was appointed Chairman of EASL International Liver Foundation (Geneva, Switzerland).

Medical Education:
MD, Duke University School of Medicine.
MMSc, Harvard University.
Residency, Massachusetts General Hospital.
Fellowship, Massachusetts General Hospital.
Current Academic or Administrative Positions:
Director, MGH Fatty Liver Clinic, MGH Gastrointestinal Unit.
Assistant Professor of Medicine at Harvard Medical School.
Area of Research interests:
Non-alcoholic fatty liver disease and the development of non-invasive biomarkers for the diagnosis and monitoring of NAFLD. Dr. Corey has lectured regionally and nationally on NAFLD.
Lipid metabolism in patients with steatosis and steatohepatitis as well as the development of non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Dr. Corey also studies the interaction between obstructive sleep apnea and fatty liver disease. Dr. Corey also participates in numerous clinical trials including studies for hepatitis B and C treatment and post-transplant prevention of hepatitis C infection.
Publications and Presentations:
Dr. Corey has more than 80 published articles.
Comments:
Clinical interests include all areas of hepatology including non-alcoholic fatty liver disease (NAFLD), viral hepatitis including hepatitis B, C and D infection, autoimmune hepatitis, cholestatic liver disease including primary biliary cirrhosis and primary sclerosing cholangitis. In addition, Dr. Corey treats patients with hereditary forms of liver disease including hemochromatosis and alpha-1-antitrypsin disease. Dr. Corey is also a transplant hepatologist and evaluates patients in need of liver transplantation and cares for patients after liver transplant. Dr. Corey also performs endoscopies including diagnostic and therapeutic upper endoscopy and colonoscopy.

Medical Education:
He received his medical degree and completed his internal medicine residency in Buenos Aires, Argentina.
Dr. Cusi completed a fellowship in Endocrinology, Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas.
He was a faculty at the University of Texas Health Science Center at San Antonio, Texas (1993-94; 1997-2011) focusing on the role insulin resistance to the development of type 2 diabetes mellitus (T2DM). He later focused on the mechanisms of nonalcoholic fatty liver disease (NAFLD) in T2DM and its impact on dyslipidemia, diabetes and cardiovascular disease. Dr. Cusi has studied extensively the role of insulin resistance, PPARs (with special interest on pioglitazone), in patients with prediabetes or T2DM and NASH (Belfort et al, NEJM 2006; Cusi et al, Annals Intern Med 2016).
Current Academic or Administrative Positions:
Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville (2011-present). He is also a faculty and researcher at the Veterans Administration Medical Center at Gainesville, FL in the Division of Endocrinology, Diabetes and Metabolism.
Area of Research interests:
Current work centers on discovering the mechanism(s) leading to NASH and searching for novel treatments.
Publications and Presentations:
Published more than 150 original articles, reviews and book chapters in a broad spectrum of peer-reviewed journals, such as the New England Journal of Medicine, Annals of Internal Medicine, Proceeding of the National Academy of Science, Journal of Clinical Investigation, Diabetes, Diabetes Care, Diabetes, obesity and Metabolism, J of Clinical Endocrinology and Metabolism, American Journal of Physiology, Hepatology, Gastroenterology and others.
He is a frequent invited lecturer to national and international meetings on the role of obesity and NAFLD in T2DM.
Comments:
Member of the NIH Clinical and Integrative Diabetes and Obesity (CIDO) study section and contributed to the 2012 and 2017 NASH guidelines of the American Association for the Study of Liver Diseases. In 2015 Dr. Cusi received from the University of Florida at Gainesville the Exemplary Teacher Award and the Clinical Research Award for outstanding achievement, research discovery, and productivity from the College of Medicine.

Medical Education:
Medical Degree at the University of Valencia, Spain. 1977
Specialization in Digestive Diseases and Internal Medicine at Hospital Clinico Universitario Valencia, 1981
Current Academic or Administrative Positions:
Professor of Medicine at University of Valencia.
Chief of Hepatology section at the Hospital General Universitario of Valencia.
Area of Research interests:
Hepatology: Viral Hepatitis B and C, NAFLD and liver cancer.
Publications and Presentations:
Publications: 142 original papers and more than 60 reviews and others; 6 books and 38 book chapters. More than 100 international lectures.
H-index: 39 Citations: 19.002
Comments:
Professor Diago is internationally known hepatologist who has served as principal investigator in more than 90 international clinical trials related to viral hepatitis, liver cancer and NASH. He has widely published and lectured about liver diseases.

Medical Education:
Dr. Duseja did his MBBS in 1988, MD (Internal Medicine) in 1992 and DM (Gastroenterology) from PGIMER, Chandigarh in 1996.
Current Academic or Administrative Positions:
Professor in the department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. For last 22 years, he is working as Faculty with focused research in the field of Hepatology.
Area of Research interests:
NAFLD, ACLF, Viral Hepatitis, HCC
Publications and Presentations:
Professor Duseja is author of more than 200 papers in reputed international and national journals including several chapters in the Gastroenterology and Hepatology text books.
Professor Duseja is also the Associate Editor of the Journal of Clinical and Experimental Hepatology (JCEH), an official journal of INASL, Associate Editor of JGH Open and is on the Editorial board of various international and national journals.
Comments:
Professor Duseja is Fellow of American Association for the Study of Liver Diseases (FAASLD), Fellow of American College of Gastroenterology (FACG), Fellow of National Academy of Medical Sciences (FAMS) and Fellow of the Society of GI Endoscopy of India (FSGEI). He is National Convener of Indian National Association for Study of the Liver (INASL) Task Force on Nonalcoholic Fatty Liver Disease (NAFLD), member of the Chronic Liver Disease Foundation (CLDF) NASH Committee, member of Asia- Pacific Working Party on NAFLD and member of Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the INASL Task Force on Hepatitis C virus, Hepatocellular carcinoma, Acute on Chronic Liver Failure and Drug Induced Liver Injury.
Professor Duseja is the former Honorary Treasurer of the Indian National Association for the Study of Liver (INASL) and has been the office bearer and member of various other scientific societies. He is a recipient of various awards and honors from National and International societies.

Medical Education:
M.D. from Saga University School of Medicine
Ph.D. from Saga University Graduate School of Medicine
Current Academic or Administrative Positions:
Assistant Director of the National Center for International Medical Research Center
Professor of Liver Center of Saga University hospital
Area of Research interests:
Clinical research on Nonalcoholic fatty liver disease and viral hepatitis
Publications and Presentations:
Professor Eguchi is a member of multiple societies and has served as the investigator in multiple projects in viral hepatitis and NAFLD. He has served as Professor and Chairman of Liver Center of Saga University hospital He is widely published with more than 110 published articles.

Medical Education:
Medical Degree from Cairo University Faculty of Medicine (1979).
Master Degree in Tropical Medicine from Cairo University Faculty of Medicine (1984).
Medical Doctorate in Tropical Medicine from Cairo University Faculty of Medicine (1990).
Current Academic or Administrative Positions:
Professor of Tropical Medicine and Hepatology,Faculty of Medicine, Cairo University
Director of the Viral Hepatitis Treatment Centers.Ministry of Health, Egypt
Founder and Head of Kasr El Aini Viral Hepatitis Center
Area of Research interests:
Hepatitis prevention, screening and treatment
Hepatocellular carcinoma
Pediatric hepatology diseases and living related liver transplantation
Publications and Presentations:
More than 190 published articles
Comments:
Professor. Esmat has served as the past president of the International Association for the Study of the Liver (IASL) (2006-2008). He is currently a board member of the strategic and technical advisory committee for viral hepatitis (STAC-Hep), WHO and member of the scientific committee for the World Hepatitis Alliance. Professor. Esmat has served as principal investigator of numerous research studies in Egypt and has has had more than 190 published articles.

Medical Education:
B.Sc. and M.Sc. (1994), Shandong Medical University, Shandong, China.
Ph.D. (1997), Shanghai Second Medical University, Shanghai, China.
Current Academic or Administrative Positions:
Professor and Director of Department of Gastroenterology at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Principal Investigator of Shanghai Key Lab of Pediatric Gastroenterology and Nutrition.
Area of Research interests:
Fatty liver, nonalcoholic fatty liver disease, alcoholic liver disease
Publications and Presentations:
Published over 700 peer-reviewed papers (including over 100 articles in SCI journals as the first and/or correspondent author, i.e, Hepatol, J Hepatol, AP&T, Cancer Let, EbioMedicine, Liver Int, and 5 book chapters in English ) with H-index 44, and 19 books as editor-in-chief, i.e, Fatty Liver Disease in China People’s Medical Publishing House. He was also the co-chairman of the Biennial Shanghai International Forum on Digestive Diseases between 2010 and 2018, and invited speaker in 20 countries.
Comments:
He was a Gastroenterologist and then also Associate Professor at Shanghai 1st People’s Hospital from 1997 to 2007. He was a Visiting Scholar of Australian National University Medical School (Canberra, Australia) from 2007 to 2008, and Visiting Professor of Cleveland Clinic Institution of Digestive Disease (Cleveland, USA) in May 2010. He was co-chairman of the Biennial Shanghai International Forum on Digestive Diseases between 2010 and 2018.

Medical Education:
Received MD from the University of Medical Sciences of Havana in 1996 and completed her residency in gastroenterology at the National Institute of Gastroenterology, in 1999.
She was obtained of Scientific Degree (PhD in medical science) in 2011 at the University of Havana.
Graduated of fellowship in Diagnosis and treatment of Early Gastrointestinal Cancer (2004) University of Tokyo, Japan (JICA).
Current Academic or Administrative Positions:
Full Professor of Gastroenterology and Senior Researcher at the University of Medical Sciences of Havana. Chief of Research at the National Institute of Gastroenterology. Before she was the Chief of Teaching Department (2006-2012), Chief of the Department of Biostatistics and Clinical Research (2012-2013). Chief of the Department of Hepatology (2013-2015). She serves as a Member of the Medical Rector's Advisory Committee for Gastroenterology Specialization. Dr Fernandez is a member of the Cuban Society of Gastroenterology, Hepatology Section and Latin-American Association for the Study of Liver Disease.
Area of Research interests:
Viral hepatitis, nonalcoholic steatohepatitis and advanced liver disease.
Publications and Presentations:
Professor Fernández had published over 40 articles and 6 book chapters/reviews, over 65 presentations.
Comments:
Professor Fernández and her research have been recognized by the Cuban Academy of Sciences Award 2014 and Annual Health Award of Cuba 2011.

Medical Education:
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.
Current Academic or Administrative Positions:
Senior clinical researcher for the Research Fund of the Flemish government.
chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp
Area of Research interests:
He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH.
Publications and Presentations:
Author/co-author of over 180 papers in peer-reviewed journals and authored several book chapters on NAFLD. He is editor of JHep Reports, the open-access journal of the European Association for the Study of the Liver.
Comments:
Prof. Francque is as scientific committee member involved in the design of several phase 2 and current phase 3 trials in NAFLD and is national and international lead PI of several of these trials. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission and by the Innovative Medicines Initiative with a focus on NASH pathophysiology, biomarker research and hepatocellular carcinoma. His clinical trial unit participates from the early days of clinical trials in NASH in many clinical trials in the field.
Prof. Francque is scientific coordinator of the Belgian Week of Gastroenterology, the Belgian national research meeting of all scientific societies in gastroenterology and hepatology in Belgium. He coordinated the Belgian guidelines on NAFLD and more recently the EASL and EASO-endorsed NAFLD patient guideline. He has recently been appointed to the governing board of the European Association for the Study of the Liver.

Medical Education:
University of Ulm
University of Luebeck
Current Academic or Administrative Positions:
Professor, Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, VCU
Area of Research interests:
Lipids and bile acids, bile formation, cholestasis, epithelial transport, molecular biology
Publications and Presentations:
Multiple publications in international peer-reviewed journals
Comments:
Dr. Fuchs clinical Specialties are Liver transplantation, fatty liver disease, viral hepatitis, autoimmune and metabolic liver disease, liver cancer, ultrasonography, elastography, endoscopy. He is widely published with over 130 articles in pubmed.

Medical Education:
MBBS from the University of Queensland (Australia), and obtained his PhD from the University of Sydney
Current Academic or Administrative Positions:
Robert W. Storr Professor of Hepatic Medicine at the Storr Liver Centre, Westmead Institute for Medical Research, University of Sydney and Head of the Department of Gastroenterology and Hepatology at Westmead Hospital and Director of Gastroenterology and Hepatology Services for the Western Sydney Local Health District
Area of Research interests:
Clinical, basic and translational research on NASH, hepatitis C, liver cancer, genetics and hepatic fibrosis
Publications and Presentations:
He has published over 412 papers, with over 31,200 citations and has an h index of 84. Is an Associate Editor for the Journal of Hepatology, and is or has been on the Editorial Board of Hepatology, Hepatology Communications, Liver International, Hepatology International and the World Journal of Gastroenterology.
The numerous international invitations to speak, include AASLD, DDW, EASL, APASL and APDW
Comments:
Professor George was a past Executive Council member of the Asian Pacific Association for the Study of the Liver and served on the council of the Gastroenterological society of Australia. Professor George is internationally known hepatologist and investigator and has published over 450 articles.

Medical Education:
Tufts University School of Medicine
Internship and Residency: Internal Medicine, New England Medical Center
Fellowship: Rheumatology, National Institutes of Health
Residency: Physical Medicine and Rehabilitation, George Washington University
Board Certification: ABIM, Rheumatology, ABPMR
Current Academic or Administrative Positions:
University Professor, George Mason University
Medical Director Outcomes Program, Beatty Center for Study of Liver Disease, Inova Health System
Director of Research, Department of Medicine, Inova Fairfax Medical Campus, Inova Health System
Area of Research interests:
Dr. Gerber main focus has been on determining relationships among human performance and perception with proteomic/metabolomic measures. This has also included development of new outcome measures for people with CLD.
Publications and Presentations:
Authored 180 peer reviewed manuscripts, 60 book chapters and 1 book and authored 4 Institute of Medicine Reports.
Comments:
Dr. Gerber has been doing clinical biomedical research for 45 years, as an intramural scientist at NIH studying human movement and function; and as a faculty investigator at Mason studying fatigue and chronic pain in people with cancer and musculoskeletal diseases. As part of the Outcomes Program at Beatty Center measuring fatigue in people with chronic liver disease (CLD) and obesity, determining relationships among human performance and self-reports combined with proteomic/metabolomic measures.
Created a PhD program for Rehabilitation Science at George Mason University. Obtained extramural funding ($4 million) from federal grants: NIH, NSF, NIDRR/NIDILRR, Henry Jackson Foundation. Recipient of many awards for teaching, research, mentorship, service to PMR and to patients with disabilities. Elected to the National Academy of Medicine (formerly,IOM).
Recipient of many awards for teaching, research, mentorship, service to PMR and to patients with disabilities. Elected to the National Academy of Medicine, formerly, Institute of Medicine.

Medical Education:
Dr. Hasmik L. Ghazinyan graduated from Yerevan State Medical University named after Mkhitar Heratsi, in 1978. Later, in 1987 she received specialization certificate from the Chair of Infections Disease of the National Institute of Health Named After Academician S. AVDALBEKYAN (NIH), Ministry of Healthcare of the Republic of Armenia.
Dr. Ghazinyan also completed a post-graduation study and Fellowship Program on infections Disease in Olbany Medical centre, NY, USA, 1996.
Current Academic or Administrative Positions:
Head of Hepatology Department, NORK Clinical Hospital of Infectious Diseases, Yerevan, Armenia
President of Armenian Hepatological Association
Area of Research interests:
Viral Hepatitis, HBV, HCV, HCC, NAFLD/NASH
Publications and Presentations:
Dr. Hasmik Ghazinyan is author of more than 160 scientific publications in local and international journals and magazines.
Attended more than 120 specialized medical conferences (local and international) as an invited speaker and moderator.
Comments:
Dr. Hasmik L. Ghazinyan is a member of EASL, APASL, IASL, CEVHAP
Member of Editorial Advisory council of scientific-practical journal Blood Armenia, since 2011
Member of Editorial Advisory council of scientific- practical journal Actual Infectology, Ukraine since 1 August 2013
Member of Editorial board of journal of Clinical and Molecular Hepotology of Korean Association for the Study of the Liver (KASL), 2015
Author of Methodical Recommendations: Management of HBV and HCV Infections in Onco/Oncoheamatological Patients in the Republic of Armenia
Member of APASL executive Council (EC) 2017
Member of THE EDITORIAL BOARD OF HEPATOLOGY INTERNATIONAL
Member of AARC working group, APASL ACLF Research Consortium
President of APASL STC on NAFLD/NASH in Yerevan, Armenia, October, 2021

Medical Education:
Dr. George Goh obtained his MBBS degree from the University of London; Guy’s Kings and St Thomas’ School of Medicine (2002)
Medical officer and registrar fellowship training at Singapore General Hospital. After Gastroenterology specialist training, he underwent further advanced subspecialty fellowship in Hepatology at the Cleveland Clinic (USA), with a research focus on non-alcoholic fatty liver disease (NAFLD).
Current Academic or Administrative Positions:
Dr. Goh is senior consultant gastroenterologist at Singapore General Hospital, Singapore. He currently leads the fatty liver service program in Singapore General Hospital. He is also an appointed Adjunct Assistant Professor at Duke-NUS Medical School and a Clinical Lecturer at Yong Loo Lin School of Medicine, National University of Singapore.
Area of Research interests:
Non-alcoholic fatty liver disease
Publications and Presentations:
Dr. Goh has published 22 pubmed articles as of November 2018
Comments:
In addition, he remains actively involved in research and is the local Principal Investigator of several ongoing international pharmaceutical interventional NAFLD trials. He has published in the fields of NAFLD, liver cirrhosis, hepatocellular carcinoma and organ transplantation, and has been an invited faculty at local, regional and international conferences. Besides appointment as fellow of Academy of Medicine, Singapore (FAMS) and member of the American Association for the Study of Liver Disease (AASLD), he is an appointed Adjunct Assistant Professor at Duke-NUS Medical School and Clinical Lecturer at Yong Loo Lin School of Medicine, National University of Singapore. He is the current Chairman of the National Foundation of Digestive Disease (NFDD), which aims to increase awareness of gastrointestinal diseases among the general public in Singapore.

Medical Education:
Wayne State University School of Medicine, Detroit, Michigan (MD)
University of Miami School of Medicine, Miami, Florida (Clinical Hepatology Fellowship)
Current Academic or Administrative Positions:
Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan
Director, Division of Hepatology, Henry Ford Health System, Detroit, Michigan
Area of Research interests:
Epidemiology and treatment of viral hepatitis, epidemiology and treatment of cholestatic and nonalcoholic fatty liver disease. Organization of multicenter liver disease collaboration consortia.
Publications and Presentations:
Authored or co-authored over 200 articles, 15 book chapters, 4 invited editorials and 1 textbook. His current H-index is 62.
Comments:
Dr. Gordon has served as an ad-hoc member of several NIH and NCI Study Sections and he is on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon was the recipient of the Distinguished Alumni Award from Wayne State University School of Medicine. He is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee. He is identified in the 2018 Highly Cited Researchers list from Clarivate Analytics
In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He is also the Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.

Medical Education:
University of Florida, Doctor of Medicine
Greenville Hospital System in Greenville, South Carolina, Internal Medicine Residency
San Antonio Uniformed Services Health Education Consortium (SAUSHEC) Wilford Hall Medical Center/Brooke Army Medical Center, Gastroenterology/Hepatology Fellowship
Current Academic or Administrative Positions:
Medical Director and President, Impact Research Institute, Waco, Texas
Area of Research interests:
Management of chronic liver disease and therapies for liver related illnesses.
Publications and Presentations:
Authored or co-authored multiple articles ad publications.
Comments:
Dr. Nadege Gunn is a Gastroenterologist and Hepatologist who focuses mainly on finding therapies for liver related illnesses. She is also a Certified Principal Investigator by the Association of Clinical Research Professionals (ACRP). Her work concentrates on linking cutting edge clinical trials in non-alcoholic fatty liver disease and gastrointestinal illnesses to the populations who need them desperately. She is a fellowship-trained Gastroenterologist and Board Certified in both Internal Medicine and Gastroenterology. She has a broad clinical research and community practice background.
Dr. Gunn is a graduate of the University of Florida College of Medicine. She completed an Internal Medicine Residency at the Greenville Health System in Greenville, South Carolina. Her Gastroenterology and Hepatology Fellowships were completed in Texas at the San Antonio Uniformed Services Health Education Consortium as an active duty member of the United States Air Force.
Prior to separating from her military practice in 2015, Dr. Gunn earned the rank of Major and acted as the Chief of Gastroenterology at Eglin Air Force Base in Florida.
Just prior to founding Impact Research Institute, Dr. Gunn served as Hepatology Consultant to Austin Gastroenterology and as the Site Lead Physician for The Liver Institute of Virginia in Newport News, Virginia. Dr. Gunn is currently an Adjunct Assistant Professor for Texas A&M College of Medicine and Dell College of Medicine at UT Austin.
Dr. Gunn is passionate about the management of chronic liver disease and is committed to providing world class care for patients. She is a Medical Advisory Member for the American Liver Foundation and the Fatty Liver Foundation.

Medical Education:
Kind Edward Medical College, University of Punjab, Lahore, Pakistan
Residency training from United Kingdom Fellowship in Hepatology, Southwestern Medical School, University of Texas, Dallas, USA
Current Academic or Administrative Positions:
Professor of Medicine, Director, Clinical Trials Unit.
Area of Research interests:
Viral hepatitis, NASH and HCC.
Publications and Presentations:
164 indexed publications to date, including the first report of hepatitis E virus super-infection causing Acute on Chronic Liver Failure.
Comments:
Chairperson, Guidelines Development Group for WHO Guidelines for the Treatment of Persons with Hepatitis C virus infection, 2016.
Chairperson, Guidelines Development Group for Revision of WHO Guidelines for the Treatment of Persons withHepatitis C virus infection, 2018.
Co-Chair, Coalition to Eradicate Viral Hepatitis from Asia-Pacific (CEVHAP),
Member, Steering Committee, International Coalition to Eradicate Hepatitis B Virus Infection (ICE-HBV),
Chair, Hepatology Interest Group, World Gastroenterology Organization.
Member, Governing Council, World Gastroenterology Organization

Medical Education:
MD, Graduated from Cukurova University Faculty of Medicine in 1992.
Internal Medicine, Completed Internal Medicine program at Ankara University Faculty of Medicine, Department of Internal Medicine in 1997
Gastroenterology Fellowship Program at Ankara University Faculty of Medicine the same university in 2000.
Current Academic or Administrative Positions:
Professor of Medicine in Department of Internal Medicine/Gastroenterology
Area of Research interests:
Viral hepatitis, hepatocellular carcinoma, NAFLD
Publications and Presentations:
Professor Ramazan Idilman has published over 135 articles in Pubmed.

Medical Education:
Emory University School of Medicine
Current Academic or Administrative Positions:
Adjunct Assistant Professor Emory University School of Medicine
Area of Research interests:
Nonalcoholic Fatty Liver Disease, Obesity
Publications and Presentations:
Publications in peer reviewed journals and several bestselling books on hormones and weight loss. Over 500 faculty lectures.
Comments:
Dr. Scott Isaacs is a board certified, and fellowship trained endocrinologist in practice at Atlanta Endocrine Associates. His private practice focuses on obesity medicine, fatty liver disease, cardiometabolic disease, dyslipidemia, diabetes, and general endocrinology.
Dr. Isaacs attended medical school at Emory University School of Medicine and continued for residency and fellowship in endocrinology. He continues his 35-year association with Emory as Adjunct Assistant Professor of Medicine in the School of Medicine. He is a diplomate of the American Board of Obesity Medicine and the American College of Physicians. He is a two-time past president of the Georgia Chapter of the American Association of Clinical Endocrinologists and is a past president of the Atlanta Chapter of the American Diabetes Association. He currently serves on the Executive Committee as Secretary of the American Association of Clinical Endocrinology (AACE) and is the co-chair of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Practice Guidelines.
Dr. Isaacs is committed to education for patients, the public and health professionals. Throughout his career, he has given more than 500 lectures, grand rounds and CME programs and serves on the planning committee and as a speaker for national meetings. He has published research in peer-reviewed journals, and has authored patient education materials, several best-selling books and has an active following on social media. He has appeared in the New York Times and is a contributor for CNN, NPR, Dr. Phil, and others.

Medical Education:
MD degree (cum laude) and then had a post-graduate training in internal medicine and gastroenterology at Nikolai Pirogov Russian State Medical University in Moscow.
Current Academic or Administrative Positions:
Chief of Gastroenterology and Hepatology at Federal Research Centre of Nutrition, Biotechnology and Food safety in Moscow, Russia.
Area of Research interests:
Pathogenesis and treatment of viral hepatitis, NASH and GI diseases
Publications and Presentations:
Dr. Isakov is the author and co-author of over 100 peer-reviewed papers as well as numerous abstracts, books, book chapters and monographs. He serves as an editorial board member of the Best Practice & Research Clinical Gastroenterology, Experimental and Clinical Gastroenterology, Voprosy Pitaniya, Voprosy Dietologii.
Comments:
Dr. Isakov was awarded Abrikosov Prize of Russian Academy of Sciences, Nikolai Pirogov Prize of Russian State Medical University and Award of Moscow government in medical research. He is a member of American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Society for Nutrition (ASN) and Fellow of American Gastroenterological Association (AGA).

Medical Education:
Medical School - Columbia University College of Physicians & Surgeons
Residency, Internal Medicine - Massachusetts General Hospital
Current Academic or Administrative Positions:
Professor, Department of Medicine
Director, Hepatology at NYU Langone Health
Area of Research interests:
Hepatitis, Fatty liver disease, Priimary biliary choangitis, primary sclerosing cholangitis
Publications and Presentations:
Dr. Jacobson has over 200 publications.
Comments:
For more than 30 years, Dr. Jacobson participated in hundreds of clinical trials on antiviral therapy for viral hepatitis, including hepatitis B and C, and I has also led a number of them. These studies have remarkably improved our ability to treat people with these conditions, including the capacity to cure nearly all patients who have hepatitis C.
Dr. Jacobson is a fellow of several major organizations, including the American College of Physicians, the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the American College of Gastroenterology, and a member of the European Association for the Study of the Liver. Recently, he was honored to be elected to a fellowship at the Royal College of Physicians in the United Kingdom.

Medical Education:
Received M.D. from Gunma University School of Medicine. After receiving his M.D., he started practicing medicine as a Hepatologist, and also involved in clinical research concerning hepatitis C virus. Received Ph.D. degree in 1999 from Gunma University. In 2000, Jjoined Dr. Masa Negishi’s laboratory at NIEHS/NIH (U.S.A) to study the roles of nuclear receptor CAR regulating the drug metabolizing enzymes.
Current Academic or Administrative Positions:
Associate Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan
Area of Research interests:
Nuclear receptors and liver disease including NASH/NAFLD.
Publications and Presentations:
On the Editorial Board of World Journal of Gastroenterology. He received the Award from the Japan Society of Hepatology and JSPS Research Fellowship Award for Japanese Biomedical and Behavioral Researchers at NIH. He has published more than 180 peer-reviewed research articles.
Comments:
Dr. Kakizaki is a councilor of the Japan Society of Hepatology (JSH), the Japanese Society of Gastroenterology (JSGE), and Japan Gastroenterogical Endoscopy Society (JGES). Dr. Kakizaki is a member of the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA).

Medical Education:
Completed medical school in Cairo University in 2001, and MSc, PhD degrees in HepatoGastroenterology from the same university, in addition to a postgraduate diploma in medical research from University of Liverpool in 2015. Professor El-Kassas had clinical and research training internships in Kyoto University, Japan, Pasteur Institute, France, l'hopital Tinon, France, Rotterdam University Hospital, Netherlands, Fresno Medical Center, University of California, San Francesco, and Health science centre, University of Calgary, Canada.
Current Academic or Administrative Positions:
Associate professor and chief of Endemic Medicine and Hepato-Gastroenterology Department, Faculty of Medicine, Helwan University, Cairo, Egypt
President of Egyptian Association for Research and Training in HepatoGastroenterology (EARTH).
Member of the executive board of Egyptian National Committee for Control of Viral Hepatitis (NCCVH).
Director of Research Support Center, and University International Ranking Unit, Helwan University.
Member of Specialized Scientific Council for Medical Research, ASRT.
Area of Research interests:
Viral hepatitis, focusing his work on the management of HCV and HBV, and their relation to hepatic carcinogenesis. NAFLD.
Publications and Presentations:
Prof. El-Kassas has participated in several collaborative research works on clinical aspects, epidemiology and public health issues related to viral hepatitis, NASH, and HCC. He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring about 60 peer-reviewed manuscripts in the field of Hepatology and Gastroenterology.

Education:
Achim Kautz has a degree in Communication Sciences (IHK, KdA)
Current Academic or Administrative Positions:
CEO of Kautz5 gUG – a non-profit project and consulting company in the health sector. At the heart of our work is the patient with all their needs and concerns. Our goal is to improve their medical care structures and quality of life in a sustainable and long-term manner.
Area of Research interests:
He has a long-standing expertise in advocacy with a special interest in translating chronic diseases (liver, metabolic) into a language that allows policy discussion with key decision makers in different health care settings (local, national, regional, and global).
Publications and Presentations:
Author/co-author of many papers in peer-reviewed international and national journals. In his career he held 100dreds of presentations and meetings with representatives of governments, politicians, and health care decision makers.
Comments:
Achim Kautz has been CEO of the German Liver Help Association, a co-founder of the European Liver Patient Association (ELPA), a co-founder of the World Hepatitis Alliance (WHA), a member of the national strategy planning group of the WHO, involved in 6 WHO resolutions. He is a member of the advisory committee of the German MoH for viral hepatitis and a member of the expert committee of the joint committee (GBA) in Germany.
He is involved in several national and international patient centric research projects in the field of NASH, HCC and PBC.
Achim Kautz is a co-author of several guidelines in the field of liver diseases, a strategic advisor of the EASL policy group, together with Sven Francque a co-ordinator of the EASL and EASO-endorsed NAFLD patient guideline.

Medical Education:
Kurume University School of Medicine (M.D.)
Kurume University Graduate School of Medicine (Ph.D.)
Current Academic or Administrative Positions:
Assistant Professor, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan
Area of Research interests:
Exercise therapy for NAFLD
Effects of anti-diabetic agents for patients with HCC
Nutritional therapy for liver cirrhosis
Publications and Presentations:
Dr. Kawaguchi has had more than 160 published articles including Gastroenterology (4), Hepatology (8), J Hepatol (2), Proc Natl Acad Sci U S A (2).

Medical Education:
Yonsei University College of Medicine
Current Academic or Administrative Positions:
Professor of Yonsei University College of Medicine.
Member of Korean Association of the Study of the Liver and Korean Liver Cancer Study Group.
Area of Research interests:
Viral hepatitis, liver fibrosis, NAFLD, hepatocellular carcinoma
Publications and Presentations:
More than 150 SCI(E) original, peer reviewed publications including Hepatology, J Hepatol, Am J Gastroenterol, Clin Gastroenterol Hepatol, Clin Cancer Res, Aliment Pharmacol Ther as primary or corresponding author.
He is a invited referee for more than 20 SCI(E) journals including Gastroenterology, Hepatology, Journal of Hepatology, etc.
Comments:
Dr. Seung Up Kim acts as Editor-in-Chief of Clinical and Molecular Hepatology, as Associate Editor of Gut and Liver, an academic editor of PLoS One, and editorial board member of Journal of Gastroenterology and Hepatology. His academic interests include ‘Molecular biology of hepatitis B virus’, ‘Immunogenetics of hepatitis virus infection’, ‘Noninvasive assessment of liver fibrosis’, and ‘Diagnosis and treatment for viral hepatitis and liver cancer’.

Medical Education:
Executive MBA degree, Copenhagen Business School (2017-2019)
Harvard Business School, Executive Education, Pasteur programme (2013-2014)
Specialist training, Gastroenterology and Hepatology, Copenhagen University Hospitals (2008-2013)
PhD. degree University of Copenhagen(2008)
MD University of Copenhagen(2001)
Current Academic or Administrative Positions:
Vice Secretary General, European Association for the Study of Liver (EASL)
Director Centre for Liver Research Odense University Hospital
DIAS Chair of Health Sciences, University of Southern Denmark
Professor and Head of Hepatology, Department of Gastroenterology and Hepatology Odense University Hospital
Area of Research interests:
My passion is research with focus on fatty liver diseases (alcohol and non-alcohol related), liver fibrosis, complications to cirrhosis and microbiome. I’m particularly interested in biomarker research throughout the full value chain from discovery to implementation and how omics and AI can be used in next generation biomarkers.
Publications and Presentations:
Scopus (oct 2022): 230 scientific publications, 9937 citations, H-index 45 (Scopus oct 2022).
Further I have contributed to 12 books and supervised 25 PhD students.
Comments:
I’m involved in and hold leader positions in a number of large research collaborations in liver diseases, including being director of FLASH: Fibrosis Fatty Liver and Steatohepatitis Research Centre Odense, Coordinator in the H2020 project GALAXY: Gut and Liver Axis in Alcoholic Liver Fibrosis and partner and PI in the H2020 projects MicrobPredict, LiverScreen and The International Human Microbiome Action and PI in the Center of Excellence Center for Functional Genomics and Tissue Plasticity. I’m involved in several international organizational activities including being member of the EASL governing board and currently serve as Vice Secretary and will become the next EASL Secretary General from June 2023.

Medical Education:
Keck School of Medicine of USC, 1994
Case Western Reserve School of Medicine, Pediatric Internship 1996
University of Kentucky Hospital, Pediatric Residency 1997
University of Colorado Children's Hospital, Fellowship in Pediatric Nutrition 2017
Current Academic or Administrative Positions:
Pediatric Healthy Lifestyle Clinic, Denver Health Medical Center
Area of Research interests:
Pediatric nutrition and NAFLD
Comments:
Pediatrician with extensive expertise in nutrition. Dr. P Kugelmas has been engaged in Pediatric NASH projects with the Global NASH Council

Medical Education:
University of Buenos Aires, Doctor of Medicine, 1987
Los Angeles County-University of Southern California, Internal Medicine Residency, 1990-1993
Cleveland Clinic Foundation, Fellowship in Gastroenterology, 1993-1995
University of Kentucky, Fellowship in Hepatology, Liver Transplantation and Advanced Endoscopy, 1995-1997
Current Academic or Administrative Positions:
Director of Hepatology and Research at South Denver Gastroenterology.
Area of Research interests:
Chronic liver disease
Publications and Presentations:
Published over 25 papers in peer-reviewed journals.
Comments:
Dr. Kugelmas is a leader in Community Practice of Hepatology and is a national lecturer on topics of chronic liver disease, has presented regularly at multiple gastroenterology, liver and transplantation annual meetings.

Medical Education:
Physician Assistant Program – The George Washington University
Current Academic or Administrative Positions:
Research Investigator at the Inova Center for Integrated Research
Member of the American Association for the Study of Liver Diseases and the Liver Fibrosis and Hepatology Associates Special Interest Groups
Area of Research interests:
Hepatitis, Non-Alcoholic Fatty Liver Disease
Publications and Presentations:
Mr. Lam has published 13 pubmed articles as of January 2020.
Comments:
In addition, he remains actively involved in research and is an investigator for several investigator-initiated research protocols and several ongoing international pharmaceutical interventional NASH trials. He has published in the fields of NAFLD and viral hepatitis. He is also a participating member in several local and national organizations for advanced practice providers (physicians assistants and nurse practitioners).

Medical Education:
PhD, Faculty of Medicine, Lund University, Sweden (2008)
Master of International Health, Copenhagen University, Denmark (2004)
Master of Foreign Service, Georgetown University, USA (1991)
Current Academic or Administrative Positions:
Co-director, Viral and Bacterial Diseases programme, Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Spain
Head of the health systems team, ISGlobal
Associate Professor at the Faculty of Medicine, University of Barcelona
Area of Research interests:
Health systems and policy, HIV/AIDS, NASH and NAFLD, viral hepatits, healt-related quality of life, COVID-19.
Publications and Presentations:
Author of more thasn 300 articles in international peer-reviewed journals and over 400 presentations in national and international congresses.
Comments:
He is Vice-Chairman of the board of the EASL International Liver Foundation, co-chair of the HIV Outcomes Coalition and a member of the Public Health and Policy Committee of the European Association for the Study of the Liver. He is co-chair of Innovations in NAFLD Care Workshop (INCBCN) and in 2020, he joined The Lancet COVID-19 Commission public health taskforce and has been advising governments, NGOs and WHO, as well as frequently appearing in the media to address pressing issues about the pandemic. He was a core co-author of the Lancet GastroHep Commission on Viral Hepatitis (2019) and the EASL-Lancet Commission: Protecting the next generation of Europeans against liver disease complications and premature mortality (2021). Prof Lazarus is an editorial board member of the International Journal of Drug Policy, HIV Medicine and the Journal of Hepatology. Previously, he worked for 11 years at WHO Europe and 3 at the Global Fund as well as founding director of Health Systems Global and board chair of the foundation AFEW International.

Medical Education:
Completed his medical degree with a specialization in hepato-gastroenterology in 1993 and obtained his PhD in 2001.
Current Academic or Administrative Positions:
Professor of Medicine at the Department of Gastroenterology and Hepatology, University Hospital of Bordeaux, France. Runs a clinical research program studying the impact of liver fibrosis and chronic liver disease on the lives of patients and novel approaches for the non-invasive evaluation and treatment of these diseases.
Area of Research interests:
Supervises a clinical research program on new drugs for the treatment of chronic hepatitis B and nonalcoholic steatohepatitis (NASH). He has been the principal investigator on various national and international clinical trials on direct-acting antivirals in hepatitis C and in NASH drugs. Supervises a clinical research program on the long-term prognosis of 20,000 patients with chronic liver diseases.
Publications and Presentations:
He published more than 250 articles in peer-reviewed journals.

Medical Education:
University of Kerala, Medical College, Trivandrum (PhD)
Current Academic or Administrative Positions:
Senior Research Scientist, Manager and Coordinator at Population Health and Research Institute (PHRI), Trivandrum and Director, Holistic Health and Research Institute, Trivandrum
Area of Research interests:
Epidemiology of G I disorders such as chronic pancreatitis, GERD, IBS, NAFLD and chronic HBV and HCV and HCC; Yoga in G I disorders.
Publications and Presentations:
Authored over 90 articles, over 5 book chapters, over 250 abstracts at the national and international scientific meetings.
Comments:
Dr Leena is currently Senior Research Scientist Manager and Coordinator at Population Health & Research Institute (PHRI), Trivandrum and also the Clinical Trial Coordinator at the Dept. of Gastroenterology, Sree Gokulam Medical College & Research Foundation, Venjaramoodu, Trivandrum. She is the Project Director of the Holistic Health and Research Institute, Medical College, Trivandrum. and Course co-ordinator of PG Diploma in Yoga Therapy course, Kerala University. She is the Co-PI of a large cohort study involving 400,000 subjects under the Urban and Rural Trivandrum Tobacco Study. (supported by CTSU, University of Oxford) (Sample size: 400, 000 males) which was initiated in 2000 and currently in the third follow up round. She is also involved in the population-based studies on GI disorders, diabetes mellitus, NAFLD and other chronic liver diseases. She is CO PI of the project “Dietary, life style and genetic factors associated with dyslipidemia, insulin resistance, non-alcoholic fatty liver disease and it’s severity in a population-based cohort in South India “(Sample size 2200) supported by: National Institute for Health Research Nottingham Digestive diseases Biomedical Research Unit (NIHR NDDBRU), Nottingham University Hospitals and University of Nottingham, UK.

Medical Education:
1969 - Universitas Indonesia - Dokter Umum
1975 - Universitas Indonesia - Spesialis Penyakit Dalam - SpPD
1989 - University of Amsterdam - Doctor of Philosophy - Ph.D
2011 - Kolegium Ilmu Penyakit Dalam - Konsultan Gastroenterohepatologi - KGEH
Current Academic or Administrative Positions:
Senior Research Scientist, Manager and Coordinator at Population Health and Research Institute (PHRI), Trivandrum and Director, Holistic Health and Research Institute, Trivandrum
Area of Research interests:
Liver biopsy and Cirrhosis
Publications and Presentations:
Dr. Lesmana has an hindex of 30, co-authored 113 publication(s) receiving 7845 citation(s).

Medical Education:
Received his MD from the National Taiwan University (in 1992) and was subsequently awarded his PhD by the Graduate Institute of Clinical Medicine at the National Taiwan University College of Medicine (2003).
Current Academic or Administrative Positions:
Professor at the Department of Internal Medicine and Graduate Institute of Clinical Medicine at the National Taiwan University College of Medicine, and a visiting staff member at Hepatitis Research Center at the National Taiwan University Hospital.
Area of Research interests:
Research interests focus on the role of host and viral factors in the pathogenesis and natural/treatment outcomes of chronic hepatitis B and C.
Publications and Presentations:
Has published more than 240 peer-reviewed research articles.
Comments:
Is the principal investigator of several multicenter clinical trials involving patients with chronic viral hepatitis B and C. His researches have been recognized by awards from the Liver Disease Prevention and Treatment Research Foundation and Professor JL Sung’s Research Foundation in Taiwan, and 2013 JGHF Emerging Leader Lectureship.

Medical Education:
Masters of Health Science in Clinical Research, Duke University School of Medicine, Durham, NC (2007).
M.B.B.S. The Armed Forces Medical College, India (1999)
Current Academic or Administrative Positions:
Professor of Medicine (with tenure)
Vice Chief, Division of Gastroenterology Department of Medicine
Director of Hepatology
Director, NAFLD Research Center
Director, Liver Epidemiology Training Program
Area of Research interests:
Research interests focus in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities.
Publications and Presentations:
Dr. Loomba has published more than 420 manuscripts and has an H-index of 111. He is among the top 1% of the globally highly cited scientists across all fields in 2019, 2020 and 2021 by Web of Science.
Comments:
Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 50 clinical trials conducted worldwide. He holds a patent on non-invasive biomarkers of NASH and fibrosis.
His research is funded by the National Institutes of Health including three R01s, three U01 (two NIDDK and one from NIAAA), core director of P30 (NIDDK) and project director P01 (NHLBI) grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.

Medical Education:
PharmD, Facuty of Pharmaceutical Sciences, Universidade Lisboa, Portugal
PhD, Faculty of Medicine, University of Manitoba, Canada
Current Academic or Administrative Positions:
Professor Physiology and Diabetology at NOVA Medical School|Faculdade Ciências Médicas, Universidade NOVA Lisboa
Portuguese Diabetes Society Council and coordinator for the national research network in diabetes.
European Society for Clinical Investigation Council.
Steering Committee of NAFLD Study Group of the European Association for the Study of Diabetes.
APDP-Portugal Council (Associação Protetora dos Diabéticos de Portugal), patient association including a devoted clinic to integrative care in diabetes including NAFLD.
Coordinator of APDP - Education and Research Centre of APDP-Diabetes Portugal
Member of the Council of the NOVA Medical School, Universidade NOVA Lisboa (NMS-UNL).
Vice-President Ernesto Roma foundation.
Area of Research interests:
Promotion and control of NAFLD, Obesity and Diabetes by unveiling mechanisms and seeking new management approaches.
Publications and Presentations:
Author of more thasn 100 articles in international peer-reviewed journals and over 200 presentations in national and international congresses.
Comments:
Professor Macedo is actively involved in several scientific Societies at national and international levels (European Association for the Study of Diabetes – EASD; International Diabetes Federation – IDF; European Society for Clinical Investigation – ESCI and Portuguese Diabetes Society. At the academic level she coordinates a PhD program with multidisciplinary approaches, dynamically enrolled in the Medical Pedagogical Council and has been enrolled in patient empowerment and disease management in the field of Diabetes and comorbidities such as NAFLD.

Medical Education:
Graduated at “Alma Mater University”, Bologna, Italy. Specialized in Internal Medicine, in Gastroenterology and in Diabetology.
Former Associate Professor of Endocrinology, later full professor of Internal Medicine and Dietetics.
Current Academic or Administrative Positions:
Retired. “Alma Mater” Professor, University of Bologna, Italy.
Honorary Professor of Non-Alcoholic Fatty Liver Disease (NAFLD), University of Aarhus, Dk (2018-2023).
Area of Research interests:
Along his career he moved from studies of cirrhosis, hepatic encephalopathy and amino acid metabolism to studies in obesity and in diabetes, linking his interests in the study of NAFLD. He was part of the FLIP (Fatty liver – Inhibition of Progression) consortium funded by European Commission, with specific interest in behavioral aspects and behavioral interventions to reduce the burden of disease.
Publications and Presentations:
Prof. Marchesini coauthored over 500 peer-reviewed publications (as of September 2022, Impact Factor: 4890; H index (Scopus): 84; Citations (Scopus): 39234)
Comments:
Prof. Marchesini is a leading expert in the study of metabolic liver disease. He pioneered research in NAFLD pinpointing the association of liver disease with metabolic syndrome. During his whole research he merged his competence in liver disease and metabolism with intensive research in the area of nutrition, diabetes and obesity, as part of his activity inside National and European Associations. A specific focus of his research is the relation between specialists and general practitioners in the diagnosis and treatment of NAFLD and the use of web-based and mobile technologies for behavioral intervention and continuous care of NAFLD patients.
In 2013-2015 he chaired the joint Commission by EASL, EASD and EASO for NAFLD Clinical Practice Guidelines and in 2019 the Italian Commission for the diagnosis and treatment of NAFLD.

Medical Education:
Medical Degree from UNAM, Mexico, in 1984. Board certified in Gastroenterology in 1990. Doctor of Medicine specialized in Gastroenterology and Hepatology. Also obtained Academic Masters and PhD degree in Medical Science at UNAM School of Medicine UNAM and Post-doctorate at the Brigham & Women’s Hospital & Harvard University, United States of America.
Current Academic or Administrative Positions:
Member of the National System of Investigators (SNI) being level III national researcher from the National Council of Science and Technology (CONACyT). Past-President of both Mexican Association of Hepatology and Latin American Association for the Study of Liver, Chief of Medica Sur Clinic Foundation/Liver Research, Editor in Chief of Annals of Hepatology (2002–2018) and Medica Sur Journal (1996-2018) and current Governor of American College of Gastroenterology for Mexico.
Area of Research interests:
Nonalcoholic Fatty Liver Disease, bilirubin metabolism, bile acids physiology, autoimmune diseases, liver cirrhosis, viral hepatitis, obesity and metabolic disorders
Publications and Presentations:
Professor Mendez-Sanchez is author of 15 books, co-author of 146 chapters in National and international books and 261 articles in PubMed.
Comments:
Dr. Mendez-Sanchez is Fellow of several professional organizations, including the American Association for the Study of Liver Disease (FAASLD); the American Gastroenterological Association (AGAF)and the American College of Gastroenterology (FACG) and International member of the European Association for the Study of the Liver (EASL).

Medical Education:
MBChB, BSc and Phd at the University of Edinburgh
Current Academic or Administrative Positions:
Director NIHR Birmingham Biomedical Research Centre
NIHR Senior Investigator
Director of Research & Knowledge Transfer for College of Medical and Dental Sciences
Director of Centre for Liver and Gastrointestinal Research
Professor of Experimental Hepatology & Hon Consultant Hepatologist
Area of Research interests:
NAFLD and Cell therapy
Publications and Presentations:
Professor Newsome has co-authored more than 150 published articles
Comments:
Professor Newsome runs the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which includes a large multi-disciplinary clinic for patients with NAFLD. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapies in NAFLD published in the Lancet and the NEJM. He is the Co-ordinating Investigator for several global NAFLD studies. He chaired the national guidelines for liver transplantation in NAFLD and sat on the NICE Guideline Development Group for NAFLD. He led the recent UK multi-stakeholder guideline group on the management of abnormal liver blood tests and led on NAFLD for the recent EASL Lancet Liver Commission. He recently completed his term as Secretary General (President) of EASL.

Medical Education:
Graduate of University College Dublin 1989, trained in hepatology at the National Liver Transplant Centre at St Vincent's University Hospital, Dublin, and the Institute of Liver Studies at King's College Hospital London completing CCST in 1999. Was appointed consultant in viral hepatitis and liver transplantation in 2000 at Kings’ College Hospital
Current Academic or Administrative Positions:
Consultant hepatologist/gastroenterologist at St James's Hospital and is Professor in Gastroenterology & Hepatology at Trinity College Dublin.
Area of Research interests:
Viral hepatitis, NAFLD, cirrhosis, haemochromatosis, and immunology.
Publications and Presentations:
Professor Norris has co-authored more than 200 published articles
Comments:
Prof Norris is a former member of the National Consultative Council for Hepatitis C, former member of the governing board of the European Association for the Study of the Liver (2007-2008), EASL Scientific Committee (2005-2008), AASLD Education Committee (2007-2009) and former committee member of the British Society of the Study of the Liver (2000-2004). She was National Specialty Director for gastroenterology/hepatology registrar training in Ireland from 2007-2012 at the Royal College of Physicians in Ireland, and Vice-Dean of Postgraduate Specialist Training 2012-2016. Prof Norris was the inaugural Clinical Lead to the National Hepatitis C Treatment Program in Ireland 2016-2017. A founding member and chair of the Irish Hepatitis C Outcomes Research Network (2012-2016), she has participated into several collaborative works on epidemiology and public health issues related to viral hepatitis.

Medical Education:
Residency: University of Southern California, 2005
Fellowship: National Institutes of Health, 2008
Fellowship: University of California, San Diego School of Medicine, 2011
Master's: Duke University School of Medicine, 2017
Current Academic or Administrative Positions:
Director of Fatty Liver Program at Cedars-Sinai Medical Center.
Area of Research interests:
The research of Mazen Noureddin, MD, focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities and exploring new treatments.
Publications and Presentations:
Noureddin M, Khoyliar C, Palmer SL. MRI, CT scan and ultrasound in the diagnosis of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2015;49(4):351-352.
Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240(6):809-820.
Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):361-379.
Noureddin M, Lam J, Peterson M, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58(6):1930-1940.
Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B, Doo E, Kleiner DE, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58(5):1644-1654.
Comments:
Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World report.
His focus is on clinical and translational research in the area of NAFLD. Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He was one of the authors who established MRI-PDFF as a precise biomarker for measurement of liver fat in patients with NAFLD/ NASH. Based on a study he published in Hepatology 2013 (among others) MRI-PDFF is increasingly being as the main outcome for NASH therapies in phase 2 clinical trials. This paper was cited in the 2017 AASLD NAFLD guidelines. He has given many invited lectures on NAFLD/NASH at national (e.g. American Gastroenterological Association, AASLD) and international society meetings and serves on several steering committees / advisory boards for industry.

Medical Education:
University of the Philippines College of Medicine.
Internal Medicine Residency at the Yale Primary Care Internal Medicine Residency Program
Gastroenterology Fellowship at the Cleveland Clinic Foundation.
Clinical Hepatology Fellowship at the National Institutes of Health in Bethesda, Maryland
Master of Public Health from Johns Hopkins University Bloomberg School of Public Health.
Current Academic or Administrative Positions:
Clinical Associate Professor at the University of the Philippines College of Medicine.
Area of Research interests:
AFLD, hepatocellular carcinoma, Hepatitis B and C, and complications of cirrhosis.
Publications and Presentations:
Dr. Ong has published more than 50 research articles and over 60 research presentations to international meetings.
Comments:
Dr. Ong has been active in liver disease research since his fellowship at the Cleveland Clinic. He subsequently worked at Liver Program of the NIDDK, NIH undr the mentorship of Dr. Jay Hoofnagle. After additional training in Liver Transplant at Inova Fairfax Hospital and Masters in Public Health at Johns Hopkins University, he worked as Staff Hepatologist at the Center for Liver Diseases, Inova Fairfax Hospital in Falls Church Virginia. Dr. Ong was highly active in Outcomes Research related to NAFLD, Viral Hepatitis and Hepatic Encephalopathy. Since 2007, Dr. Ong has joined University of the Philippines College of Medicine as a hepatologist and has been involved in a number of projects, including Organizing Committee of 2019 APASL in Manila Philippines.

Medical Education:
Kochi Medical School, graduated program, JAPAN, Ph.D., 1998
Kochi Medical School, JAPAN, M.D., 1990
Current Academic or Administrative Positions:
Associate Professor of Medicine, Department of Endoscopy, Kochi Medical School Hospital, Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University
Area of Research interests:
Clinical and experimental research on Nonalcoholic fatty liver disease
Publications and Presentations:
Dr. Ono has had more than 190 published articles

Medical Education:
MD degree from State University of New York in Albany and residency training in Internal Medicine at Long Island Jewish Medical Center in New York (1993). He completed the fellowship training in Gastroenterology-Hepatology at the SUNY in Stony Brook in 1999. Prior to joining the faculty at NYU School of Medicine, Dr. Pan has held the academic positions of and Associate Professor at the Mount Sinai School of Medicine in NY (2003-2011).
Current Academic or Administrative Positions:
Professor of Medicine (2012-present) at the Division of Gastroenterology and Hepatology, NYU Langone Medical Center, NYU School of Medicine in NY. (www.med.nyu.edu/biosketch/panc01). He is also a Chair of the Online Learning Committee in the American Association for the Study of Liver Diseases (2016-2019).
Area of Research interests:
Chronic liver diseases including viral hepatitis and non-alcoholic fatty liver disease.
Publications and Presentations:
Dr. Pan has presented his work as original articles in the New England Journal of Medicine, Lancet, Hepatology, Journal of Hepatology, and other high impact journals. He also serves as a primary writer for the expert consensus guidelines on hepatitis B in the US and the international expert consensus guidelines on viral hepatitis.
Comments:
Recognized by his colleagues, Dr. Pan has received many awards and accolades for his contributions to medical sciences and patient cares, including the James D. Bruce Memorial Award for Distinguished Contributions in Preventive Medicine from the American College of Physicians, Outstanding Contribution Award of the Chinese Society of Infectious Diseases, and Certificate of Service Appreciation from the American Cancer Society. He is a Master of the American College of Physicians and Fellow of AASLD. As an expert and key opinion leader in his specialty, Dr. Pan serves as a keynote speaker at many international scientific congresses and expert consultant meetings of World Health Organization.

Medical Education:
MD (1986), PhD (1997), Medical School of National and Kapodistrian University of Athens, Greece
Gastroenterology at Tzaneion Hospital of Piraeus, Greece
Hepatology fellowship at the Royal Free Hospital of London, UK.
Current Academic or Administrative Positions:
Professor in Medicine and Gastroenterology at Medical School of the National and Kapodistrian University of Athens and Director of the Academic Gastroenterology Department of Laiko Hospital of Athens, Greece; Co-ordinator of the Viral Hepatitis Committee and of the Committee for the Implementation of the Hellenic National Plan for hepatitis C elimination; President of the Hellenic National Transplant Organization.
Area of Research interests:
Chronic liver diseases including viral hepatitis and non-alcoholic fatty liver disease.
Publications and Presentations:
Dr. Papatheodoridis has authored or co-authored more than 300 papers published in PubMed journals having total impact factor of more than 2000 and more than 15000/22000 citations (h-index 60/73) in Scopus/Google Scholar. He was Associate Editor of Liver International and has served as Editorial Board member of other international journals and as reviewer for all gastroenterology/Hepatology journals, many major internal medicine journals (New Engl J Med, Lancet, Ann Intern Med, BMJ etc), ILC/EASL-UEGW abstracts, EU 7th Framework Programme for research and Horizon 2020. He has given more than 160 lectures, chaired more than 50 lectures/round tables and presented more than 300 abstracts in international meetings.

Medical Education:
University of Miami School of Medicine
Post-graduate training: University of Texas, Southwestern, Dallas, Texas
Post-graduate training: Baylor University Medical Center, Dallas, Texas
Current Academic or Administrative Positions:
Medical Director, Center for Hepatitis C, Wellstar Atlanta Medical Center, Atlanta, Georgia
Professor of Medicine, Emory School of Medicine, Atlanta, Georgia
Professor of Medicine, Medical College of Georgia, Augusta, Georgia
Area of Research interests:
Viral hepatitis and non-alcoholic liver disease
Publications and Presentations:
Has over 70 peer-reviewed papers, many of which are in high impact journals, including The Lancet, Journal of the American Medical Association (JAMA), Annals of Internal Medicine, Gastroenterology, Hepatology and Clinical Infectious Disease.
Comments:
Dr. Pearlman is a Fellow of the American Association for the Study of Liver Disease (FAASLD). He is certified by the American Academy of HIV Medicine (AAHIVS) and has sat on the Board of Directors for the American Liver Foundation's SouthEast chapter. He is active in both patient care and teaching physicians both internal medicine and hepatology, and has been a recipient of a myriad of teaching awards.

Medical Education:
University of Pará (MD)
University of São Paulo School of Medicine Gastroenterology/ Hepatology/ PhD/ Postdoctorate
Current Academic or Administrative Positions:
Associate Professor of the Department of Gastroenterology, University of São Paulo School of Medicine.
Chief of Hepatology Branch of Hospital das Clínicas, Department of Gastroenterology, University of São Paulo School of Medicine.
Vice-Coordinator of Postgraduate Course of , Department of Gastroenterology, University of São Paulo School of Medicine.
Area of Research interests:
Pioneering research in Brazil in non-alcoholic fatty liver disease, genetics. Microbiome, HCC as well experimental models as well clinical trials.
Publications and Presentations:
Authored over 200 articles, 2 books, over 15 book chapters, over 500 abstracts at the international scientific meetings and over 300 faculty lectures. His current H-index is 40 (may 2023).
Comments:
Claudia P. Oliveira, MD, PhD, FAASLD, is Associate Professor of the Department of Gastroenterology, University of São Paulo School of Medicine, Chief of Hepatology Branch of Hospital das Clínicas, Department of Gastroenterology, University of São Paulo School of Medicine and Vice-Coordinator of Postgraduate Course of Department of Gastroenterology, University of São Paulo School of Medicine. Dra. Oliveira completed Residency in Internal Medicine, Gastroenterology, Hepatology Fellowship and PhD at University of Sao Paulo School of Medicine, where she became interested in hepatology research. Her training period was funded by Brazil Government (residency) and FAPESP (Fundação de Amparo a Pesquisa do Estado de São Paulo) (PhD) and, Family Alves de Queiroz Foundation (Post-doctorate). The last grant focuses on NAFLD. Following my Post-doctorate in Hepatology, I did some international collaborations with European and Americans groups that study NAFLD. In 2008 I became Assistant Professor of University of Sao Paulo School of Medicine and in 2012 Associate Professor of the same University. In 2015 I joined VCU as a Visiting Professor and continued to develop my skills in clinical and translational research that extended into microbiome research in NAFLD patients. My initial research efforts focused in genetic studies in NAFLD and more recently in microbiome, lipidomic e metabolomics studies with international collaborations. I also have HCC experimental and clinical studies. I am a senior hepatologist who have published extensively on NASH, a global cause of liver disease. I am considered a key opinion leader in NASH and the National PI for several international trials in the field. In my own lab, I have performed ground-breaking work on the role of the microbiome and genetic and experimental studies in animals and individuals with NASH. I am a strong researcher an active member and fellow of AASLD, EASL, and ALEH and, do more than fifteen years of clinical and experimental research in NASH. I have many collaborations with European and American University with more than 200 published manuscripts in the NASH and HCC field. My H indices: is 40(ISI); 50 (Google Scholar) and my CV is available Lattes: http://lattes.cnpq.br: 8930335778301812. In addition to research, Dra. Oliveira has been actively involved in teaching students, residents and fellows.

Medical Education:
Sawai Man Singh Medical College, India
VCU Medical Center, USA
Current Academic or Administrative Positions:
Associate Professor, Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, VCU
Area of Research interests:
Gastroenterology, Hepatology and Liver Transplantation
Publications and Presentations:
Multiple publications in international peer-reviewed journals

Medical Education:
National and Kapodistrian University of Athens, Greece (MD, PhD)
University of Miami, School of Business Administration (MBA)
Sismanoglion General Hospital National and Kapodistrian University of Athens Greece: Internal Medicine Residency
University of Miami School of Medicine, ABIM Research Pathway, Internal Medicine Residency
University of Miami School of Medicine, Fellowship in Gastroenterology and Hepatology
University of Miami School of Medicine, Fellowship in Hepatology and Liver Transplantation (Clinical and Research)
Current Academic or Administrative Positions:
Professor and Chief Gastroenterology and Hepatology, Medical Director Liver Transplantation
Rutgers-New Jersey Medical School and University Hospital
Department of Pharmacology, Physiology & Neuroscience Rutgers- New Jersey Medical School: Professor
New York Medical College School of Medicine: Adjunct Professor of Medicine
Area of Research interests:
Liver Transplantation, Liver failure, Cirrhosis and complications, Viral Hepatitis, Alcohol associated liver disease, non-alcohol associated liver disease, liver cancer, Autoimmune liver diseases
Publications and Presentations:
Dr. Pyrsopoulos has published over 100 Refereed Original Articles 6 books, numerous Monographs and Chapters, numerous web reports and abstracts. He presents worldwide on Liver and Digestive Diseases.
Comments:
Nikolaos Pyrsopoulos, M.D., Ph.D., M.B.A., F.A.C.P., AGAF, FACG. FRCP (Edin), is Professor and Chief of Gastroenterology and Hepatology and Medical Director of Liver Transplantation at Rutgers New Jersey Medical. He is a member of numerous national and institutional committees and currently he is the chair of the AASLD finance committee and a section councillor for the AGA Liver and Biliary section. He has participated in multiple international and national research projects. His vision of excellence in patient care, provides outstanding education to the fellows, residents and students and promoting the science of medicine by conducting research.

Medical Education:
Graduated from Stanley Medical college, Madras, India.
Fellowship trained in Hepatology at University of Miami under De.Eugene Schiff in Gastroenterology and Hepatology at University of Missouri
Current Academic or Administrative Positions:
Clinical asst. professor, Dept of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Area of Research interests:
Very much interested and actively involved in education of the Collegues and the Public.
Publications and Presentations:
Published in Hepatology, NewEngland Journal of Medicine, Journal of Hepatology, and other Journals.
Comments:
Dr Ravendhran has been actively involved in over 100 clinical trials in NASH, Hepatitis C and Hepatitis B. He is a member of AASLD and actively involved in related activities, such as SIG. He has widely published with about 39 articles in pubmed.

Medical Education:
MD (1996), University of Illinois, Chicago, IL
Residency in Internal Medicine (1999), University of Chicago, Chicago, IL
Fellowship in Gastroenterology and Hepatology (2002), Northwestern University, Chicago, IL
Current Academic or Administrative Positions:
Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program.
Area of Research interests:
Include non-alcoholic fatty liver disease/NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and other metabolic co-morbidities and the occurrence of NASH after liver transplantation
Publications and Presentations:
Dr. Rinella has published more than 60 peer reviewed papers and given numerous presentations nationally and internationally on the topics of NAFLD, transplantation, liver disease in pregnancy and complications of cirrhosis. recently established a multicenter consortium to study the risk factors for liver disease recurrence and outcomes of patients transplanted for NASH cirrhosis (NailNASH Consortium).

Medical Education:
University of Melbourne
Current Academic or Administrative Positions:
Head of Hepatology, Alfred Health
Clinical Professor of Gastroenterology, Monash University
Chair Australian Liver Association Clinical Research Network
Area of Research interests:
Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease, Autoimmune Liver Disease, Chronic Viral Hepatitis, Non-invasive Markers of Liver Disease; Clinical Trial Design
Publications and Presentations:
Author of 180 publications, 2 book chapters, 350 abstracts; Associate Editor Seminars in Liver Disease.

Medical Education:
Medical School, University of Seville, Sevilla, Spain. 1990
Digestive Diseases department. Virgen del Rocío University Hospital, Servicio Andaluz de Salud, Andalucía, Spain. 1994
Current Academic or Administrative Positions:
Full Professor of Medicine at University of Seville, Director of Digestive, liver and inflammatory diseases at Institute of Biomedicine of Seville.
Area of Research interests:
NAFLD (pathophysiology, personalised medicine, diagnostic methods and therapy) Hepatitis C (elimination) and Hepatic Encephalopathy.
Publications and Presentations:
Publications: 305; H-index: 52 Citations: 13.635

Medical Education:
First MBBS - 1976
Second MBBS - 1978
Final MBBS - 1979
Current Academic or Administrative Positions:
Interim Chair of the Division of GI, Hepatology, and Nutrition and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Area of Research interests:
Hepatology, NAFLD
Publications and Presentations:
Dr. Sanyal has authored more than 350 articles in such publications as Cell Metabolism, Nature Medicine, New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, and the Journal of Infectious Diseases and has a H-index of 102.
Comments:
Arun J. Sanyal, M.D., is a Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. He currently is the Interim Chair of the Division of GI, Hepatology and Nutrition. Dr. Sanyal has been named Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Dr. Sanyal also serves as Chairman of the NIH NASH Clinical Research Network, the NIMBLE consortium and the Liver Forum for NASH and fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of end stage liver disease. He has served as a member of numerous advisory boards to pharmaceutical companies and also the liver center at Yale University. He chaired the hepatobiliary pathophysiology study section of the NIH and was a founding member of the Hepatology committee of the American Board of Internal Medicine. He has also served as Secretary as well as President of the American Association for Study of Liver Diseases. He has been continuously funded by the NIH since 1995 and is the principal investigator of four active NIH grants. He is the recipient of the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017 and the Distinguished Achievement Award from the AASLD in 2018.

Medical Education:
University of Mainz, Germany. 2002
Tulane University in New Orleans, USA. 2002
Albert-Einstein College of Medicine, New York, USA.
Current Academic or Administrative Positions:
Professor of Medicine and Director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany.
Area of Research interests:
Main research interest focus on translational sciences of liver injury, the development of therapeutic interventions and novel biomarkers in acute and chronic liver disease.
Comments:
Prof. Schattenberg acts as lead principal investigator in phase II and III clinical trials, is a member of the scientific committee of the United European Gastroenterologist (UEG) and a member of the Editorial Board of Hepatology and the Alimentary Pharmacology & Therapeutics.
He launched the Metabolic Liver Research Program at the University Medical Center in Mainz and he is board-certified in Internal Medicine and Gastroenterology & Hepatology and Infectious Disease.

Medical Education:
MD from Osaka University Medical School (Osaka Japan). Graduate School of Medicine, Osaka University (Osaka Japan).
Clinical and Research fellow, Department of Surgery, Graduate School of Medicine, Osaka University (Osaka, Japan).
Bariatric fellow, Department of Digestive and Bariatric Surgery and Adelaide Bariatric Centre (Adelaide, SA, Australia).
Visiting assistant professor, Division of Bariatric Surgery, Department of gastrointestinal surgery, University of Minnesota Medical School (Minneapolis, MN, USA).
Current Academic or Administrative Positions:
Consultant surgeon, co-director Weight Loss and Metabolic Surgery Center Minimally Invasive Surgery Center
Chief, Division of Clinical Research
Area of Research interests:
Effects of GI surgery on the pathophysiology of type 2 diabetes mellitus especially for Asian
Surgical treatment for gastroesophageal reflux diseases (GERD)
Surgical education, technical aspects of bariatric surgery, endoscopic suturing
Publications and Presentations:
Dr. Seki has published over 45 peer reviewed articles in NAFLD and Bariatric surgery.

Medical Education:
Dr Serfaty received his medical degree from University of Paris-Sud. He completed his residency as clinical fellow at Erasme Hospital, ULB University, Bruxelles, Belgium. He completed a clinical fellowship and a research fellowship in hepatology at Saint-Antoine Hospital, Pierre and Marie Curie University, Paris 6. He served as senior fellow in hepatology at Saint-Antoine Hospital, Paris.
Current Academic or Administrative Positions:
Lawrence Serfaty is Professor of Hepatologyand Gastroenterology, Chief of the Digestive Diseases Department, Hautepierre Hospital, University of Strasbourg, France. Before moving to Strasbourg University in 2017, he was the Viral and Metabolic Liver Unit Head and Associate Professor of Medicine in the Department of Hepatology at Saint-Antoine Hospital. He is Associate Researcher in the INSERM UMR_S938, University Pierre and Marie Curie, Paris 6, France.
He is also the co-director of HBV cure group at ANRS, Paris.
Area of Research interests:
Dr Serfaty began his research career studying viral HCV in the early 1990s and then focused on potential mechanisms of steatosis and its role in fibrogenesis in chronic HCV. He then extended his field of research to non-alcoholic fatty liver disease (NAFLD), by investigating mechanisms of liver injury associated with insulin resistance in obese patients as well as those with HIV-associated lipodystrophy. He is now focusing his research on global epidemiology of NAFLD and mechanisms of fibrogenesis in NASH.
Publications and Presentations:
Author of more than 180 articles in international peer-reviewed journals, with an H-index of 47. More than 500 presentations in national and international congresses. Comments:
Dr Serfaty has been involved in a number of trials evaluating anti-HCV direct-acting antivirals and new molecules in NASH. He is a member of the French Association for the Study of the Liver (AFEF) and the European Association for the Study of the Liver (EASL).

Medical Education:
DM from University of Kerala, Medical College, Trivandrum.
Current Academic or Administrative Positions:
Head, Dept. of Gastroenterology, Sree Gokulam Medical College and Director, Population Health and Research Institute
Area of Research interests:
Clinical trials, Epidemiology of G I disorders such as chronic pancreatitis, GERD, IBS, NAFLD and chronic HBV and HCV and HCC
Publications and Presentations:
Authored over 90 articles, over 5 book chapters, over 300 abstracts at the national and international scientific meetings. Comments:
I am currently Head of the Dept of Gastroenterology in Sree Gokulam Medical College. I was the Director of Clinical Epidemiology Research and Training Centre. I was the core faculty who has built up the Clinical Epidemiology Unit and later Resource and Training Centre and trained faculty in Research methodology and M Phil in Clinical Epidemiology. I played a key role as Coordinator for the Global Medicine program Karolinska Institute, Sweden and Govt Medical College Trivandrum from 1995-2006 and coordinator Linneus Palme Exchange Program 2001-2006. My main areas of research are tropical pancreatitis, hepatitis B and C, NAFLD, GERD and tuberculosis. I am the lead investigator in the Trivandrum Tobacco study with a male Cohort of 400,000 subjects being followed up from 2000 supported by NIH and University of Oxford and other studies such as GERD, Non alcoholic fatty disease supported by NHS and Nutrition supported by IARC, WHO unit, Lyon. I have studies supported by Karoliinska University in areas of GERD and Gut microbiota. I am the Executive Director of an NGO, Population Health and Research Institute and all studies in the community are coordinated through this organization which has a core team of 22 social workers and 4 office staff and Dr Leena is the senior Manager and Scientist who coordinates the work.

Medical Education:
University College of Medical Sciences, University of Delhi, India
Current Academic or Administrative Positions:
Associate Professor, University of South Dakota and Sanford School of Medicine
Transplant Hepatologist, Avera McKennan University Hospital and Transplant Institute
Chief Clinical Research Program, Avera Transplant and Human Genetics Research Institutes
Area of Research interests:
Non-alcoholic fatty liver disease and NASH; Alcohol-related liver disease and Alcoholic hepatitis;
Hepatorenal Syndrome; and Metabolic / Genetic liver diseases especially Porphyria
Publications and Presentations:
Authored over 160 peer-reviewed publications; 18 book chapters, guest edited 2 journal supplements, edited 2 books, and over 180 conference abstracts at national and international conferences and over 100 faculty invited lectures / talks. H-index is 38.
Comments:
Ashwani K. Singal MD, MS completed internship at the Bronx VA hospital affiliated with the Mount Sinai School of Medicine in NY, gastroenterology fellowship at the UT Medical Branch Galveston TX, and transplant hepatology fellowship at the Mayo Clinic, Rochester MN. During his gastroenterology fellowship at the UTMB in Galveston TX, he also obtained Master's in Clinical Sciences degree with expertise in statistics and epidemiology. After serving as faculty at the University of Alabama at Birmingham until September 2018, Dr. Singal joined the growing transplant program at the Avera Medical Group and Transplant Institute in Sioux Falls SD. In addition to head the clinical research program at the Avera, he also directs the hepatology elective course for senior medical students at the Sanford Medical School of the University of SD. Dr. Singal's research has been funded through the NIDDK, NIAAA, ACG, and the industry resources. Apart from regularly reviewing research grants for the AASLD and AGA, Dr. Singal has led writing the practice guidelines for the 'American College of Gastroenterology (ACG)' on alcohol-related liver disease and co-authored guidelines for vascular disorders of the liver including portal vein thrombosis. Currently, he is also co-authoring practice guidelines on nutritional management of patients with liver disease. He is Editor-in-Chief of the 'Translational Gastroenterology Hepatology'; Associate Editor for 'Journal of Clinical Translational Hepatology' 'PLoS One' 'Digestive Liver Disease' and is on editorial board of over 10 journals including 'Journal of Hepatology' and 'Liver Transplantation'. Apart from the Schering Plough transplant hepatology AASLD fellowship award, he has been awarded the prestigious Edgar Achkar Visiting Professorship by the ACG for his presentation on "Management of Hepatorenal Syndrome Before and After Liver Transplantation" and "Management of Porphyria" at the University of Iowa. Currently, Dr. Singal Chairs the Special Interest Group of the AASLD on 'Alcohol-related Liver Disease'.

Medical Education:
MD from Catholic University Medical College, Seoul, Korea (2001)
Ph.D. from Catholic University Graduate School, Seoul, Korea (2014).
Current Academic or Administrative Positions:
Associate professor, Division of Hepatology and Gastroenterology, Department of Internal medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea.
Area of Research interests:
Hepatitis B virus and its related diseases (especially, hepatocellular carcinoma). My current research interests are the role of Extracellular Vesicles (EVs) in the fields of NAFLD
Publications and Presentations:
Dr. Song has published more than 30 peer-reviewed research articles.
Comments:
Dr. Song is also the principal investigator of several multicenter clinical trials involving patients with chronic viral hepatitis B, C, and hepatocellular carcinoma.

Medical Education:
Faculty of Health Sciences, University of Cape Town: MBChB, MMed and PhD
Fellow of the College of Physicians of South Africa: FCP(SA)
Fellow of the Royal College of Physicians, London: FRCP
Current Academic or Administrative Positions:
Head of the Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Area of Research interests:
Hepatitis B and hepatitis C, drug-induced liver injuries, autoimmune liver diseases, non-alcoholic fatty liver disease, hepatocellular carcinoma and liver transplantation.
Publications and Presentations:
Authored or co-authored 150 articles, 10 book chapters, 155 abstracts at international scientific meetings and given 100 International invited presentations.
Comments:
Wendy Spearman is Head of the Liver, Porphyria and Liver Transplant clinics at Groote Schuur Hospital. She completed her 2-year Hepatology Fellowship under Professors Ralph Kirsch and Simon Robson at the UCT/MRC Liver Research Centre in 1991 and obtained her PhD in 2008 from the University of Cape Town on “The effect of two novel C-type lectins, Ba100 and Ba25, isolated from the venom of the puff adder, Bitis arietans on T lymphocyte proliferative responses.” She is actively involved in outreach Liver education programmes and was appointed by the International Association of Providers of AIDS Care to develop Training modules on the management of Hepatitis B for sub-Saharan Africa. She is the co-lead of the ‘Viral Hepatitis in sub-Saharan Africa” Project ECHO Clinic programmes promoting delivery of care for patients with viral hepatitis in under-resourced regions and was appointed by WHO Africa as the Lead consultant to develop the National Guidelines on the management and prevention of viral hepatitis in South Africa. She is a member of the International Advisory Board of The Lancet Gastroenterology and Hepatology Journal.

Medical Education:
Saga Medical School, Saga, Japan (1996 - 2002)
Graduate School of Medicine, Saga University (2007 - 2011)
Current Academic or Administrative Positions:
Associate professor of the Division of Metabolism Diabetes and Endocrinology
Vice President of the Liver Center, Saga University Hospital, Faculty of Medicine, Saga University
Publications and Presentations:
Dr. Takahashi published over 60 articles, over 10 book chapters and a number of presentations at the international and domestic scientific meetings.
Comments:
Dr. Takahashi is experienced basic research, clinical study and trial. Among many research awards, he received The Best of The Liver Meeting 2019 AASLD. He was a research fellow of Joslin Diabetes Center of Harvard Medical School and his research interest includes metabolism of liver, skeletal muscle and adipose tissue, exercise and translational research of obesity/diabetes as well as NAFLD.

Medical Education:
Nicolae Testemitanu State University of Medicine and Pharmacy of Moldova
Current Academic or Administrative Positions:
Head of the Department of Gastroenterology, Nicolae Testemitanu State University of Medicine and Pharmacy of Republic of Moldova
Head of the Department of Gastroenterology and Hepatology, Republican Clinical Hospital „Timofei Mosneaga”, Republic of Moldova
Area of Research interests:
Hemodynamic changes in liver cirrhosis, portal hypertension, NAFLD, viral hepatitis.
Publications and Presentations:
Author of over 100 publications in national and international journals, 2 monographs, 10 National Clinical Guidelines, and over 100 oral presentations at national and international scientific meetings. Editorial board member in 2 national medical journals.
Comments:
President of Society of Gastroenterology and Hepatology of the Republic of Moldova, member of the European Association for the Study of the Liver (EASL), National Representative from the Republic of Moldova at the European Crohn's and Colitis Organization (ECCO).
President of the organizing committee of the annual national scientific events: the Autumn Conference of Gastroenterology and Hepatology, the Summer School of Gastroenterology and Hepatology, the National Congress of Gastroenterology and Hepatology, member of the organizing committee of the annual conference dedicated to International NASH day in the Republic of Moldova.

Medical Education:
Professor of Medicine, Experimental and Clinical Hepatology, Medical University of Graz, Austria (2005 – 2010)
Associate Professor of Medicine, Medical University of Graz, Austria (2000 – 2005)
Fellow, Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Graz, Austria (1997 – 1999)
Postdoctoral Research Associate, Department of Internal Medicine and Liver Center, Yale University School of Medicine, New Haven, CT (1994 – 1997)
Fellow, Department of Internal Medicine, University of Graz, Austria (1991 – 1994)
Studies of Medicine, University of Graz, Austria (1982 – 1991)
Current Academic or Administrative Positions:
Professor of Medicine, Chair of Gastroenterology and Hepatology, Medical University of Vienna, Austria (since 2010)
Guest Associate Editor Journal of Hepatology (since 2020)
Visiting Professor at the Oslo University Hospital, Norwegian PSC Research Center (2016 – 2019)
External Advisory Committee, Center for Basic Research in Digestive Diseases at the Mayo Clinic, Rochester (2016 – 2018)
Associate Editor Seminars of Liver Disease (since 2016)
Executive Board at the Center for Sepsis, Control and Care at the University Jena (since 2015)
Associate Editor Hepatology (second term) (since 2011)
Council Member, United European Gastroenterology Federation (2009 – 2013)
Scientific Committee Member, European Association for the Study of the Liver (Vice Secretary 2007-2009) (2006 – 2010)
Council Member of the Austrian Society for Gastroenterology and Hepatology (President 2014-2016) (since 2010)
Delegate of the Medical University of Graz to the Austrian Science Foundation (2003 – 2010)
Head of the Liver Study Group of the Austrian Society for Gastroenterology and Hepatology (2002 – 2008)
Deputy-Secretary of the Austrian Society for Gastroenterology and Hepatology (2000 – 2002)
Associate Editor Journal of Hepatology (2000 – 2009)
Area of Research interests:
Pharmacological treatment of fatty liver and cholestatic liver disease. Mechanisms of cell injury in cholestatic and fatty liver disease. Molecular regulation of hepatobiliary ABC transporters and bile acid signaling in cholestatic and fatty liver disease.
Publications and Presentations:
More than 500 Pubmed-listed papers, H-index: 74
More than 250 invited lectures at international scientific meetings

Medical Education:
M.D. from Mahidol University, Faculty of Medicine, Thailand. Ph.D. in medicine from Chulalongkorn University. M.Sc. in Clinical Translational Science, CTS, from Mayo Clinic, Mayo Graduate School. Research Fellow in Clinical Liver Research, Division of Gastroenterology and Hepatology, Mayo Clinic.
Current Academic or Administrative Positions:
Assistant to President, for Planning and budget, Chulalongkorn University, Bangkok, Thailand (https://www.chula.ac.th/en/about/team)
Area of Research interests:
Nonalcoholic steatohepatitis (NASH/ NAFLD)
Chronic liver diseases and liver complications
Hepatocellular carcinoma
Diseases burden of GI and Liver in Thailand
Gastrointestinal bleeding
Publications and Presentations:
Sum of the Times Cited 1,613
Sum of Times Cited without self-citations 1,592
Citing Articles without self-citations 1,420
Average Citations per Item 8.27
H-index: 21 from all to present
Comments:
Professor Sombat is Fellow of American Association for the Study of Liver Diseases (FAASLD 2018), member of Asia- Pacific Working Party on NAFLD and member of Gut and Obesity in Asia (GOASIA) working group. He is also an active member of the APASL ACLF Research Consortium; AARC.

Medical Education:
Kapodistrian University of Athens, Greece
Current Academic or Administrative Positions:
Professor of Hepatology, UCL Institute for Liver and Digestive Health, UCL
Head of Centre for Metabolic Liver Diseases, UCL Institute for Liver and Digestive Health, UCL
Consultant Hepatologist, Sheila Sherlock Liver Centre, Royal Free Hospital
Area of Research interests:
NAFLD, non-invasive fibrosis assessment, cirrhosis and portal hypertension
Publications and Presentations:
Authored over 260 publications in peer reviewed journals, over 500 abstracts in scientific conferences, over 200 faculty lectures.
Current h-index is 61 (June 2022).
Comments:
Professor Emmanuel Tsochatzis (MD, MSc, FEBTM, FRCP, PhD) is a Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London. He is Head of the Centre for Metabolic Liver Disease in ILDH and a member of the Baveno steering committee for portal hypertension. His main research interests include non-alcoholic fatty liver disease, cirrhosis and portal hypertension and non-invasive assessment of liver fibrosis.
Professor Tsochatzis finished his specialty training and PhD in Hippokration General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. He is the recipient of the Rising Star in Gastroenterology prize by the UEG and the EASL Physician Scientist Fellowship.
His work on the cost-effectiveness of non-invasive fibrosis tests has informed the World Health Organization (WHO) guidelines on diagnosis and treatment of both HBV and HCV. He has designed and implemented a primary care pathway for NAFLD referrals to secondary care. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program in NAFLD. He has published more than 260 articles in peer-reviewed journals. He served a member of the EASL Governing Board from 2019 to 2022 and was a chair of the EASL Scientific Committee in 2021-22. He has received funding for his research from NIHR, EASL and EU Horizon 2020.

Medical Education:
Nicolae Testemitanu State University of Medicine and Pharmacy of Moldova
Current Academic or Administrative Positions:
Professor of the Department of Gastroenterology, Nicolae Testemitanu State University of Medicine and Pharmacy of Moldova
Area of Research interests:
Epidemiological and clinical aspects of viral hepatitis, NAFLD and IBD
Publications and Presentations:
Author of over 300 publications, including 3 monographs, 106 articles in national and international journals, 4 chapters in textbooks, 10 Clinical National Protocols; over 150 oral presentation at the international scientific meetings. Editorial board member in 2 national and 2 international medical journals.
Comments:
Project manager or principal/senior investigator in 5 National Projects in the frame of the State Program, 8 International Projects and 2 Bilateral Projects (Moldovan-German, Moldovan-Romanian).
Member of the Governing Board of Association for the Study of Liver Disease from Moldova
Member of the Governing Board of European Crohn's and Colitis Organization (ECCO) as the National Representative from Moldova
Regular member of several professional international organizations, including the EASL, UEG, ECCO and national gastroenterological and hepatological organizations from Moldova, Romania, Russia, Ukraine.

Medical Education:
University of California, San Francisco, School of Medicine (MD)
Stanford University School of Medicine (MS Epidemiology and Clinical Research)
California Pacific Medical Center (internal medicine residency)
Stanford University School of Medicine (gastroenterology fellowship)
Current Academic or Administrative Positions:
Assistant Clinical Professor of Medicine, Director of Research and Education, Division of Gastroenterology and Hepatology, Alameda Health System
Director of Research, Gastroenterology Fellowship, California Pacific Medical Center
Secretary, Northern California Society for Clinical Gastroenterology
Area of Research interests:
Epidemiology, outcomes, and health services research in chronic liver diseases with a focus on NAFLD, alcoholic liver disease, viral hepatitis, and hepatocellular carcinoma.
Publications and Presentations:
Authored over 140 publications and over 150 abstracts at national and international scientific meetings. H-index 30 (google scholar January 2020).

Medical Education:
The Chinese University of Hong Kong (MBChB, MD).
Current Academic or Administrative Positions:
Professor, Department of Medicine and Therapeutics, the Chinese University of Hong Kong.
Head, Division of Gastroenterology and Hepatology, Prince of Wales Hospital.
Area of Research interests:
Epidemiology, non-invasive assessment and treatment of nonalcoholic fatty liver disease.
Publications and Presentations:
Authored over 350 articles, over 10 book chapters and over 100 abstracts at international scientific meetings. His current H-index is 70 (December 2019).

Medical Education:
M.D. from the Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey (2002)
Residency in internal medicine, Uludag University, Medical School, Bursa, Turkey (2007)
Gastroenterology fellowship, Marmara University, School of Medicine, Istanbul, Turkey (2011)
Current Academic or Administrative Positions:
Associate professor of medicine at the Marmara University in 2012. Director of the Institute of Gastroenterology in 2014 and of professor of medicine in 2017. President of the Turkish Fatty Liver Study Group within the Turkish Association for the Study of the Liver (TASL). Member of the European Association for the Study of Liver (EASL) and serves as principal investigator in ongoing phase II/III clinical trials of nonalcoholic steatohepatitis (NASH), of which he is the leading recruiter.
Area of Research interests:
Noninvasive imaging techniques to diagnose liver fibrosis and NAFLD, with a special emphasis on transient elastography − reflecting a logical path of investigations aimed at targeting liver biopsy to patients at high risk only.
Publications and Presentations:
Dr. Yilmaz has published more than 100 peer-reviewed research papers and has a h-index of 37 (January 2019).
Comments:
One of the most renowned Turkish clinical hepatologist specializing in nonalcoholic fatty liver disease (NAFLD), he has introduced and systematically validated various non-invasive serum biomarkers of NASH, including fibroblast growth factor 21 and cytokeratin 18 (CK18) fragments.

Medical Education:
Professor Yoon earned his MD at the Catholic University of Korea in 1985. He trained in Hepatology and Gastroenterology at Seoul St. Mary’s Hospital, The Catholic University of Korea from 1992 to 1994. He then subsequently trained as research fellow in Molecular Hepatology Laboratory, MGH, Harvard Medical School, Boston, USA from 1996 to 1998.
Current Academic or Administrative Positions:
Professor of the division of Hepatology and Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Area of Research interests:
Professor Yoon has been principal investigator in several international multicenter researches on antiviral therapy against hepatitis virus B and C, and target therapy for HCC
Publications and Presentations:
Professor Yoon has published more than 300 authored and co-authored original articles on the viral hepatitis B and C, NASH, and HCC. He had also written chapter on molecular diagnostics of HCC in the textbook “Principles of Molecular diagnostics and personalized cancer medicine”.
Comments:
Professor Yoon serves as the Vice president of Korean Association of Internal Medicine. He works as a director of Liver Cancer Center in Seoul St. Mary’s Hospital and Catholic University Liver Research Center. Professor Yoon holds scientific membership in numerous professional associations in Korea and is a member of the American Association for the Study of Liver Diseases (AASLD), EASL and APASL. He served as a secretary general of Korean Association for the Study of the Liver (KASL) from 2013 to 2015. Also, He served as a secretary general of APASL STC 2016 in Busan. Currently, he is a vice president of Korean Association of Internal Medicine. He works as a director of Liver Cancer Center in Seoul St. Mary’s Hospital and Catholic University Liver Research Center.

Medical Education:
MBBS (1994), National University of Singapore
MMed (Int Med) (2000)
Fellow of Academy of Medicine (Gastroenterology) (2003)
PhD, NUS (2010)
Current Academic or Administrative Positions:
Chair, University Medicine Cluster. NUHS
Head, Department of Medicine. NUS
Vice Chairman Medical Board, NUH
Senior Consultant, Division of Gastroenterology and Hepatology
Adjunct, Cancer Science Institute
Adjunct, Genome institute of Singapore, ASTAR
Area of Research interests:
Include liver progenitor cells, their mechanistic roles and potential for therapeutic applications in liver failure, liver cancer and NAFLD
Publications and Presentations:
70 publications to date
Comments:
Dr. Dan Yok Young obtained his medical degree (MBBS) from the National University of Singapore in 1994 He is a gastroenterologist and hepatologist having obtaining his MRCP(UK) and MMed (Int Med) in 2000 and Fellow of Academy of Medicine (Gastroenterology) in 2003. He spent 2 years at University of Washington studying liver stem cells under the mentorship of late Prof Nelson Fausto which led to his PhD from NUS in 2010.

Medical Education:
M.D.,Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (1989)
Ph.D. Graduate Institute of Medical Science, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan (2000)
Current Academic or Administrative Positions:
Attending Physician, Hepatobiliary Division, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Distinguished Professor, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Adjunct Professor, Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan
Adjunct Professor, College of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan
Vice President, Kaohsiung Medical University, Kaohsiung, Taiwan
Area of Research interests:
Molecular epidemiology of viral hepatitis
HBV/HCV virology, viral kinetics
Translational research of antiviral treatment for HBV and HCV
NAFLD/NASH
Hepatocellular carcinoma
Publications and Presentations:
Authored over 350 articles, over 3 book chapters, over 200 abstracts at the international scientific meetings and over 100 faculty lectures. His current H-index is 39 (Jan 2019)
Comments:
Ming-Lung Yu, MD, PhD, is a Distinguished Professor at the College of Medicine, Kaohsiung Medical University, Taiwan. Professor Yu, a board-certified internist and gastroenterologist, is currently teaching at the Kaohsiung Medical University and Kaohsiung Medical University Hospital. Currently, he is also a Adjunct Professor at College of Biological Science and Technology, National Chiao-Tung University, Hsin-Chu, Taiwan, and at Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Professor Yu’s research interests in epidemiology and natural history of viral hepatitis have led him to publish more than 350 journal and review articles. Professor Yu has won numerous awards over his career in recognition of his research. In addition to his academic and clinical achievements. Professor Yu also holds various editorial roles with several scientific journals some of which include PLoS ONE, World Journal of Gastroenterology, and Korean Journal of Hepatology. He also frequently serves as a reviewer for major international journals in medicine, gastroenterology and hepatology, such as The Lancet, Gastroeneterology, Hepatology, Gut, Journal of Hepatology, Clinical Infectious Disease, Canadian Medical Association Journal, Thorax, Ontotarget, Pharmacology and Therapeutics, Scientific Reports and Journal of Infectious Diseases.

Medical Education:
BS.c Nutrition Sciences in the Agriculture Faculty, Hebrew University, Israel (1998)
Ph.D Epidemiology and Preventive Medicine, Sackler School of Medicine, Tel Aviv University, Israel (2007)
Tel-Aviv Medical Center, Department of Gastroenterology and Hepatology, Israel (2008)
Current Academic or Administrative Positions:
Head of School of Public Health, Faculty of Social Welfare and Health Sciences University of Haifa
A member of the EASL Policy and Public Health Committee and the United European Gastroenterology (UEG) Policy and Public Health Committee.
Founder of the Gastroenterology forum of the Israeli dietitians’ association.
Area of Research interests:
Major research focus is on non-alcoholic fatty liver disease (NAFLD).
Publications address a wide spectrum of issues regarding lifestyle, nutritional and behavioral epidemiology and chronic morbidity, mortality and metabolic status.
Publications and Presentations:
Prof. Zelber-Sagi has published more than 150 peer-reviewed research articles.

Medical Education:
MD from Wenzhou Medical University, Wenzhou, China (2008)
Ph.D. from Wenzhou Medical University, Wenzhou, China (2016)
Current Academic or Administrative Positions:
Associate professor, NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, China.
Area of Research interests:
Clinical, basic and translational research on NASH.
Publications and Presentations:
Dr. Zheng has published more than 100 peer-reviewed research articles.
Comments:
Dr. Zheng had founded the PERSONS platform and has dedicated to the development of its infrastructure since 2016-12-07.
PERSONS is the acronym for Prospective Epidemic Research Specifically Of NASH. The database is an ongoing prospective cohort consisting of more than 930 cases of biopsy-proven NAFLD (2019-07-01) and supported by a multidisciplinary team. The team boasts its advantage in patient data collection across multiple fields of medicine including nutrition, sports, hepatology, endocrinology, cardiology, psychology, pathology, and radiology. The team of doctors specialized in each of these fields contribute in a consistent manner to ensure continuity and steady growth of database. Moreover, biobank including blood, urine, stool, pathology slides (digitized by scan), and liver tissue samples, are collected and stored in the same day of biopsy.

Medical Education:
MD, Marmara University School of Medicine, Istanbul, Turkey (2005)
Residency in Infectious disease and clinical microbiology, Marmara University School of Medicine (2011)
Research fellow, Betty and Guy Beatty Center for Integrated Research (2020)
Current Academic or Administrative Positions:
Research Investigator at Center for Integrated Research, Inova Fairfax Hospital, Falls Church Virginia.
Area of Research interests:
Epidemiology, outcomes, and health services research in chronic liver diseases with a focus on Nonalcoholic fatty liver disease (NAFLD), viral hepatitis, and hepatocellular carcinoma.
Publications and Presentations:
Dr. Golabi has more than 70 published articles over 100 abstracts at international scientific meetings. H-index 26 (google scholar July 2022).
Comments:
Member of the American Association for Study of Liver Diseases (AASLD) and serves as coordinator in ongoing phase II/III clinical trials of nonalcoholic steatohepatitis (NASH).

Medical Education:
University of Iowa, BSN
Georgetown University, MS
George Mason University, PhD
Current Academic or Administrative Positions:
Research Investigator at Center for Integrated Research, Inova Fairfax Hospital, Falls Church Virginia.
Area of Research interests:
Non-alcoholic fatty liver disease, patient reported outcomes, health-related quality of life, economic analysis and outcomes research in liver disease.
Publications and Presentations:
Numerous articles, 5 journal supplements, 5 book chapters, numerous abstracts at national and international scientific meetings.
Comments:
Linda Henry, PhD, RN is a research investigator for Inova Health Systems in Falls Church, VA and for the Guy and Betty Beatty Center for Integrated Research at Inova Fairfax Medical Campus. Dr. Henry earned her nursing degree from the University of Iowa in 1984 and then went on to serve in the United States Army as a critical care nurse. After completing her active-duty time, Dr. Henry continued to serve as a reserve officer in the Army Medical Corps while pursuing her masters in critical care nursing at Georgetown University graduating as a “Superior Student”. Following her obtainment of her masters’ degree, Dr. Henry was a clinical nurse specialist in several critical care units as well as holding teaching positions at Lagrange College in Georgia and the University of South Carolina. When her husband’s military assignment brought them back to the Washington DC area, Dr. Henry pursued her doctorial studies at George Mason University in Fairfax, VA and was awarded the Research Dissertation Award upon graduation from the College of Nursing and Health Science in 2006. Dr. Henry’s first post- doctoral position was with the Cardiac Surgery Research team at the Inova Heart and Vascular Institute where her research focus was on patient outcomes to include health related quality of life following cardiac surgery. She joined Dr. Younossi’s research team in 2014 first as a consultant and then as a full-time employee. She has assisted Dr. Younossi in his pioneering research in NAFLD, patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. Dr. Henry also is actively involved in teaching students, residents and fellows while serving as the Research Lead for the Medicine Service Line General Medicine Academic Pod (Critical Care, Emergency Department and Hospitalists) for Inova Health System.

Medical Education:
Masters in Bioscience and Business Management, George Mason University
Bachelor’s degree in Health Science, George Mason University
Current Academic or Administrative Positions:
Director of Research and Business Operations, Center for Outcomes Research in Liver Diseases (COR-LD)
Area of Research interests:
Non-alcoholic fatty liver disease, viral hepatitis, diabetes, obesity, cirrhosis, patient reported outcomes, health-related quality of life, economic analysis and outcomes research in liver disease.
Publications and Presentations:
Co-authored over 100 research papers in peer-reviewed journals, and over 150 abstracts at national and international scientific meetings.
Comments:
Fatema H. Nader is the Director of Research & Business Operations at CORLD. She is responsible for overseeing and implementing new projects and leads the research team to ensure all research activities are conducted in accordance with regulatory requirements in research. In addition, she has a secondary role in the oversight of new business partnerships, joint ventures, and alliances. Prior to her appointment, Fatema had over ten years of experience in Research and Development.
Her clinical experience in research includes the coordination of Hepatology studies for over eight years. Prior to managing clinical trials, she worked as a Clinical Research Associate monitoring clinical research at Parexel International. Fatema received her Bachelor’s degree in Health Science and her Master’s in Bioscience and Business Management at George Mason University. She also holds national certification through the Association of Clinical Research Professionals as a Certified Clinical Research Coordinator (CCRC).

Education:
Statistics, Iowa State University, MS/PhD
Current Academic or Administrative Positions:
Research investigator for Inova Health Systems in Falls Church, VA and for the Guy and Betty Beatty Center for Integrated Research at Inova Fairfax Medical Campus.
Area of Research interests:
Epidemiological research, patient reported outcomes, health-related quality of life, economic analysis and outcomes research in liver disease with a focus on NAFLD, NASH, viral hepatitis, cirrhosis, and hepatocellular carcinoma.
Publications and Presentations:
Authored and co-authored over 50 research papers in peer-reviewed clinical and molecular biology journals, and 80 abstracts at scientific meetings.
Comments:
Dr. Paik earned his statistics PhD degree from Iowa State University in 2009. Following his PhD degree, Dr. Paik was a faculty and director of statistical consulting service at University of Toledo, establishing a statistical consulting program to serve the research needs of the university, mentor students, and build a formal mechanism for interacting with the research community in industry. After joining INOVA health system in 2017, as a senior biostatistician and research investigator, Dr. Paik is a proven leader and individual contributor with 10 years of successful experience in epidemiological and health-related studies, large-data base [National Health and Nutrition Examination Survey (NHANES), National Vital Statistics System (NVSS), Global Burden of Diseases (GBD), National Impatient Sample (NIS), Nationwide Readmissions Database (NRD), Medicare data)], economic analysis, and statistical support of clinical trials research.

Education:
MS in Applied Mathematics, Moscow Institute for Physics and Technology (MIPT), Moscow, Russia
PhD in Bioinformatics, Nanyang Technological Univesity, Singapore
Current Academic or Administrative Positions:
Director of statistical services, Center for Outcomes Research in Liver Diseases (COR-LD)
Research investigator at Beatty Center for Integrated Research, Inova Fairfax Hospital
Area of Research interests:
Epidemiological research, patient-reported outcomes, health-related quality of life, outcomes research in liver disease with a focus on NAFLD, NASH, viral hepatitis, cirrhosis, and hepatocellular carcinoma.
Publications and Presentations:
Authored and co-authored over 150 research papers in peer-reviewed clinical and molecular biology journals, and over 200 abstracts at scientific meetings.
Comments:
Dr. Stepanova earned her PhD degree in bioinformatics from Nanyang Technological University in 2009. Following the PhD degree, Dr. Stepanova joined the newly reorganized Center for Liver Diseases at Inova Fairfax Hospital as a biostatistician. Later, she left to head the department of statistical services at the Center for Outcomes Research in Liver Diseases, a CRO which provided a wide range of data analysis services to pharmaceutical companies with a focus on patient-reported outcomes. In 2021, she joined Inova Health System again in the role of research investigator. Dr Stepanova co-authored more than 150 peer-reviewed manuscripts in medical journals including Hepatology, Gastroenterology, Lancet, JAMA.